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ABSTRACT
CELL-BASED THERAPIES FOR ISCHEMIC CARDIOMYOPATHY–
INVESTIGATIONS OF INTRAMYOCARDIAL RETENTION AND SAFETY OF
HIGH DOSE INTRACORONARY DELIVERY OF C-KIT POSITIVE CARDIAC
PROGENITOR CELLS, AND THERAPEUTIC UTILITY OF A NOVEL
POPULATION OF CARDIAC MESENCHYMAL STEM CELLS EXPRESSING
STAGE-SPECIFIC EMBRYONIC ANTIGEN– 3 (SSEA-3)
Matthew C. L. Keith, MD
March 18, 2016
Over the last decade attempts at reducing morbidity and mortality of patients with
chronic heart failure have been made via the development and implementation of novel
cell based therapies. Substantial advances in cell based therapies with indications of
efficacy have been shown along with a robust safety profile. Despite these advances,
there is a substantial unmet need for novel therapies, specifically addressing repair and
regeneration of the damaged or lost myocardium and its vasculature. Accordingly,
cardiac cell-based therapies have gained attention. Various cell-types have been utilized,
including bone marrow-derived mononuclear cells, bone marrow-derived mesenchymal
stem cells, mobilized CD34+ cells, and more recently, cardiosphere-derived cells and
cardiac-derived c-kit positive progenitor cells. Early studies have suggested a potential of
cell-based therapies to reduce cardiac scar size and to improve cardiac function in
patients with ischemic cardiomyopathy. However, variability of results has been observed
necessitating

improvement

of

current

vi

methodologies

related

to

optimizing the cell type(s), infusion techniques, timing, dosage, acuity related to ischemic
injury, and perhaps repeat dosing over time among others, all the while ensuring
complete and total patient safety. Accordingly, present efforts and goals of my research
are aimed at i.) Optimizing methodologies utilized within the recent phase I clinical trial
(SCIPIO) that showed intracoronary infusion of 1 million c-kit positive cardiac
progenitor cells was safe with indications of efficacy in cardiac repair, as well as, ii.)
Development of a novel cell based approach with a newly discovered cardiac cell type.
Within the present dissertation, I explored the impact of coronary stop-flow on
cardiac retention of intracoronarily infused c-kit positive cardiac progenitor cells given
that balloon inflation in a non-stented coronary artery is inherently dangerous, especially
in already damaged hearts. I demonstrate that intracardiac retention with or without stopflow is equivalent and balloon inflation confers an undue risk to patients. Furthermore, I
investigated the safety of intracoronary infusion of 20 million c-kit positive cardiac
progenitor cells in pigs, an equivalent dose 40 times larger than was used in the SCIPIO
trial. High dose of cells delivered intracoronarily is safe and does not result in myocardial
injury or functional deficit. Therefore, larger doses may reasonably be utilized in future
clinical trials. Finally, I describe a novel adult cardiac cell type that maintains expression
of an embryonic stem cell associated marker, stage-specific embryonic antigen (SSEA)-3,
resides within the native adult heart, and can be isolated and utilized for cardiac repair as
a cell based therapy.
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CHAPTER I
CELL BASED THERAPIES FOR CARDIAC REPAIR

Introduction
Cardiovascular disease accounts for more than 30 % of global mortality making it
the largest contributor to death worldwide. In the U.S., coronary heart disease accounts
for approximately 17 million cases annually1, 2, and there are approximately 5-6 million
patients who currently have a diagnosis of heart failure. The most prevalent cause of
heart failure is the loss of viable, functioning myocytes which are replaced by
noncontractile scar after myocardial infarction, although heart failure from nonischemic
causes is quickly becoming more prevalent.3 Nevertheless, the majority of treatment
options (medical therapy, catheter-based or surgical revascularization for earlier stages,
and mechanical support for later stages) employ strategies to limit further scar formation
and curtail deleterious adverse cardiac remodeling while enhancing or supplementing the
function of residual myocardium.4, 5 While some therapies have improved mortality and
work to provide what is essentially a palliative relief of heart failure symptoms, the issue
of replacing, reducing, or transforming non-viable scar tissue to functional, contractile
and supporting cells remains the ultimate goal. To this end, recent efforts within
regenerative medicine have been aimed at adoptive transfer of various stem cell
populations in an attempt to accomplish this “holy grail”.
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Stem cells are undifferentiated, clonal, self-renewing cells that possess a multi-lineage
differentiation potential toward terminal mature phenotypes.6 Multiple classifications of
stem cells exist that describe the degree of lineages to which one cell may commit. Cells
that can differentiate to all of the body’s cell types are termed pluripotent or totipotent
(such as embryonic stem cells), and others with differentiation limited to one or more
lineages of a particular organ are termed unipotent or multipotent progenitors
respectively.6 Within this framework various types of stem cells, both pluripotent and
multipotent, have been evaluated for their utilities in the treatment of heart failure with
the goal to curatively replace damaged cardiac tissue and not simply to delay progression
of disease.7, 8
The recent explosion of regenerative medicine has led to the exploration of a wide
variety of cell types and their respective cardiac differentiation potentials, both in vitro
and in vivo. Knowledge of developmental biology and identification of cellular markers
associated with known stem/progenitor phenotypes have enabled identification of
candidate cell types that may have cardiomyogenic potential and repair damaged hearts.
These include pluripotent embryonic stem cells and induced pluripotent stem cells (and
their derivatives) as well as postnatal stem cells that persist into adulthood. Among
postnatal cells, populations both intrinsic to the heart (c-kit+ cardiac progenitor cells and
cardiosphere derived cells), and extrinsic to the heart (bone marrow and adipose derived
cells) are under investigation. Importantly, how, when, and the dosage of these progenitor
cells that are administered to damaged hearts have been found to drastically impact safety
and efficacy of cell based therapy affecting engraftment, longevity, and therapeutic
response, which further adds tremendous complexity independent of the intricate cellular
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biologic processes. Intuitively, cells of cardiac origin have demonstrated superior ability
to adopt more mature cardiac phenotypes9, likely secondary to genetic predisposition
related to chromatin structure and arrangement, than that of progenitors not of cardiac
origin. Moreover, cardiac progenitor cells have demonstrated more robust myocardial
reparative effects via a variety of mechanisms independent of their direct differentiation
capacity.9 Of these, c-kit+ cardiac progenitor cells have been the most widely
investigated.10 These cardiac progenitor cells have largely been the focus of our
investigations here within the Institute of Molecular Cardiology at the University of
Louisville. A brief overarching review of past and present cell based modalities that have
been evaluated for cardiac repair and regeneration is provided below with expanded focus
on c-kit+ cardiac progenitor cells as they are specifically relevant to the present work.
The limitations and gaps in knowledge associated with individual modalities and
methodologies are highlighted to lay out the rational for the newly conducted studies
described within the present dissertation.

Cell based therapies for heart failure: Extracardiac cell populations
Skeletal Myoblasts
Skeletal myoblasts are cells derived from satellite cells, a skeletal muscle
progenitor cell population located beneath the basal membrane of myofibers. Satellite
cells undergo proliferation in response to injury and promote repair and regeneration of
skeletal muscle via differentiation into new myotubes and muscle fibers.11, 12 They are
easily obtained from muscle biopsies, rapidly expandable in vitro, and have shown
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resistance to hypoxic and ischemic conditions.13, 14 Accordingly, skeletal myoblasts were
the first cells to be tested in preclinical15 and clinical16 studies of HF.
The ability of skeletal myoblasts to promote cardiac repair and recovery has been
evaluated in both preclinical and clinical models of HF. 17-19 Studies using both
intramyocardial and intracoronary administration of myoblasts demonstrated formation of
myotubes and viable skeletal muscle-like grafts within damaged cardiac tissue. Myoblast
administration was associated with attenuation of adverse ventricular remodeling,
decreased interstitial fibrosis, and improvement of cardiac performance after ischemic
injury. Beneficial effects of myoblasts, other than direct supplementation contractility,
are mediated by the correction of the imbalance between matrix metalloproteinases
(MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) involved in
extracellular matrix (ECM) remodeling as well as activation of intrinsic cardiac stem
cells via the secretion of growth factors.20
The first human transplantation of myoblasts was performed by Menasche et al. in
patients with HF secondary to ischemic injury.16, 21 Injection of myoblasts into a scarred
left ventricular (LV) region at the time of coronary artery bypass grafting (CABG) was
associated with a significant improvement in LV function and NYHA classification.
However, some treated patients experienced dangerous arrhythmias, specifically,
ventricular tachycardia, necessitating implantation of internal cardioverter-defibrillators
(ICDs). The electrical instability of treated hearts is due to the lack of electromechanical
coupling, and failure of differentiated myotubes to express key gap junction proteins
involved in cardiac excitation-contraction coupling, namely connexin.22 This
phenomenon is likely due to the fact that myoblasts transplanted in injured hearts form
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skeletal (striated) muscle fibers rather than cardiac muscle.16, 22 Myoblasts have proven to
be unipotent lacking multipotent plasticity to adopt alternate muscle phenotypes.
Menasche et al. conducted MAGIC, a phase II randomized, placebo-controlled, doubleblind trial that examined the effects of intramyocardial injection of skeletal myoblasts (at
two doses: 400 or 800 millions) plus CABG vs. CABG alone (controls) in 97 patients
with severe LV dysfunction (LV ejection fraction [EF] between 15-35%). No significant
difference in cardiac function or occurrence of malignant arrhythmias between patients
receiving myoblasts and controls at the end of 6 months was observed.21 Other
investigators have used catheter-based intramyocardial injection of skeletal myoblasts in
ischemic HF. However, no tangible benefits to LV function or patient quality of life
were able to be reproducibly obtained that mirrored those in preclinical models.
Presently, attempts at improving cardiac function and ameliorating HF through the use of
myoblasts have been all but completely abandoned.20
Bone marrow cells
Unfractionated bone marrow mononuclear cells (BMMNCs) are a heterogeneous
population composed of mesenchymal stem cells (MSCs), hematopoietic stem cells
(HSCs) such as CD34+ cells, and endothelial progenitor cells expressing CD133 (EPCs),
as well as more committed cell lineages. BMMNCs, and thereby all the cellular subtypes,
can be easily obtained in large numbers by standard technique using density gradient
centrifugation and do not require extensive culture or in vitro expansion.23 They have the
advantage of being able to be utilized shortly after isolation thus maximizing therapeutic
utility and maximal preservation of intrinsic differentiation potential that may be
diminished by prolonged culture in vitro.23-25 Nevertheless, conflicting results have been
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obtained with preclinical models of acute MI and chronic HF.25 In sheep and pig models
of ischemic heart failure, BMMNCs (injected directly into the scar tissue) produced no
improvement in LV function (although one study reported increased angiogenesis and
reduction in infarct size).23 In contrast, studies in dogs and rats have reported
improvement in myocardial function and increased angiogenesis.23
Clinical trials utilizing BMMNCs to treat ischemic heart failure have yielded less
than exciting results of efficacy although overwhelming safety has been observed without
any teratogenicity.23 Perin et al. were the first to evaluate the safety and efficacy of
autologous BMMNCs, injected transendocardially in patients with ischemic HF
demonstrating statistically significant improvement in LVEF and a reduction in endsystolic volume in cell-treated patients.26-28 Observations by other investigators using
BMMNCs seemed to support these findings.29, 30 However, other trials have failed to
show any tangible benefit of BMMNCs in the setting of acute or chronic ischemic cardiac
injury.31, 32 The reasons for discrepant results are not apparent. Additional studies using
intracoronary infusion of BMMNCs in patients with HF have also been conducted.
Similarly, mixed results have been obtained related to efficacy. Without exhaustively
comparing the numerous clinical trials, it may best serve to hypothesize that variations in
dosages of cells, cellular consistency of specific phenotypes such as CD34+ stem cells or
MSCs, route of administration such as intramyocardial vs intracoronary, site of injection
such as peri-infarct border zone or direct cell injection into the scar, and timing of cell
administration after injury , i.e. chronicity of myocardial dysfunction, may all impact the
efficacy of BMMNC therapy.
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As is easily seen, these aforementioned factors apply much more broadly to cell
based therapies in general and contribute to the totality of lacking knowledge related to
not only the optimal cell type to administer to sick hearts to induce functional recovery,
but also the how, when, and where to infuse these cells.
In efforts to determine if specific cellular subsets within the bone marrow may
offer superior beneficial effects related to cardiac functional improvement, studies have
utilized purified mesenchymal stem cells (MSCs)33 as well as CD34+ bone marrow cells.
MSCs, also known as bone marrow stromal cells, are a subset of non-hematopoietic bone
marrow cells that are multipotent and plastic-adherent under in vitro expansion culture
conditions. MSCs have demonstrated chondrogenic, adipogenic, and osteogenic
differentiation potential.33-35 MSCs have also been reported to differentiate into
cardiomyocytes36, 37 and endothelial cells38, although this cardiogenic potential remains
controversial39, 40 as no mature cardiomyocytes with complete functional sarcomeric
apparatus has been observed to arise from MSCs in vitro. In vivo, mature cardiomyocytes
observed to possibly arise from implanted MSCs have largely been attributed to fusion
events in which MSCs and native cardiomyocytes merge to form one cell.40 MSCs
typically express the cell surface markers CD105, CD73, CD90, CD29, CD44, and
CD166 but lack hematopoietic markers (CD45, CD34 and CD14/CD11b).34, 35, 41
The results of MSC administration in animal models of chronic heart failure have
demonstrated salubrious effects of MSC therapy using various intramyocardial and
intracoronary injection techniques. Studies utilizing autologous MSCs injected directly
into myocardial scar, reduced infarct size and attenuated further deleterious LV
remodeling in a porcine model of ischemic cardiomyopathy (ICM).42 Intramyocardial
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injection of MSCs in rodent models of both ischemic and nonischemic cardiomyopathy
have shown improvement in indices of cardiac function and angiogenesis along with
reduced myocardial fibrosis.42-46 These and other preclinical studies provided the
groundwork for randomized, double-blind, placebo-controlled studies using autologous
and allogeneic MSCs in patients with chronic ischemic LV dysfunction undergoing
CABG (PROMETHEUS; NCT00587990)47 as well as the POSEIDON trial conducted by
Hare et al.42 The latter additionally compared three doses of autologous or allogeneic
MSCs (20, 100, and 200 ×106 cells) in patients with ischemic cardiomyopathy and
demonstrated that all doses favorably impacted patient functional capacity, quality of life,
and ventricular remodeling. Further trials using intramyocardial injection of autologous
and allogeneic MSCs in ischemic and nonischemic CM are currently underway,
specifically, the CONCERT and SENECA phase I/II clinical trials which were conceived
and designed here at the University of Louisville within the Department of
Cardiovascular Medicine in conjunction with the National Heart, Lung, and Blood
Institute (NHLBI) sponsored Cardiovascular Cell Therapy Research Network (CCTRN).
I was fortunate to have made substantial contributions to these endeavors under the
guidance of my mentor, who is the primary investigator of these studies, Dr. Roberto
Bolli.
Hematopoietic stem cells reside in the bone marrow and differentiate into cells of
both myeloid and lymphoid lineages centrally within the bone marrow. EPCs, on the
other hand, are mobilized into peripheral blood, often in response to ischemic injury, and
differentiate into endothelial cells peripherally promoting neovascularization (reendothelialization).48, 49 CD34 is a typical surface marker of both HSCs and EPCs.50
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Thusly, CD34+ cells have the capacity to give rise to all blood cell types as well as
endothelial cells (<1% of nucleated cells in the blood are CD34+). Autologous CD34+ cell
transplantation has been performed in patients with ischemic51 and nonischemic52, 53
cardiomyopathy. Injection of CD34+ cells into the peri-infarct regions of the left ventricle
during coronary bypass surgery produced greater improvement in left ventricular ejection
fraction than did coronary bypass alone.51 Additionally, a study by Vrtovec et al.
concluded that intracoronary infusion of CD34+ cells led to a modest increase in
functional endpoints of ejection fraction and 6-min walk distance and a decrease in levels
of the cardiac stress marker NT-proBNP.52, 53 Importantly, these beneficial effects were
sustained over time. Additional studies by the same group have shown reproducibility of
these results related to cardiac function as well as provided data on the effective
intracardiac doses responsible for patient response to CD34+ bone marrow cell therapy.
Adipose-derived MSCs
Similar to bone marrow, adipose tissue contains a pool of multipotent stem cells,
designated as adipose-derived MSCs that are able to differentiate into not only mature
adipocytes but also aforementioned cell types of the mesenchymal lineage.54 Adiposederived MSCs have also demonstrated the capacity to upregulate cardiac proteins
although this differentiation is incomplete as no organized, functional sarcomeric
structure has thus far been able to be obtained, similar to other studies using bone marrow
derived MSCs. Nevertheless, adipose derived MSCs administered in animal models of
heart failure have shown beneficial effects, mirroring bone marrow MSC preclinical
studies.54 For example, using a cell sheet technology, Miyahara et al. reported that
transplantation of monolayer MSCs into infarcted myocardium reversed wall thinning
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and resulted in improved ejection fraction.55 In another study, the effects of transplanting
undifferentiated or cardiac pre-differentiated adipose-derived MSCs were compared with
those of unfractionated BMMNCs in a rat model of chronic ICM.56 One month after
transplantation into infarcted hearts, undifferentiated adipose-derived MSCs improved
EF, augmented angiogenesis, and decreased fibrosis to a greater degree than that
observed with adipose-derived cardiomyogenic cells or BMMNCs injection.
Additionally, intramyocardial injection of adipose derived MSCs just 1 week after
coronary occlusion abrogated the declinate in myocardial contractile function and
enhanced post infarction angiogenesis in rodents.57 Clinical trials utilizing adipose
derived MSCs are currently underway.58
Embryonic stem cells (ESCs) and ESC-derived cells
Embryonic stem cells (ESCs) are pluripotent cells harvested from the inner cell
mass of pre-implantation-stage blastocysts.59, 60 When cultured in suspension, allowing
sphere formation during in vitro proliferation leading to formation of embryoid bodies,
both mouse (m) and human (h) ESCs have demonstrated the capacity to differentiate into
cells of all three germ layers, namely, ectoderm, endoderm, and mesoderm (including
cardiac myocytes, endothelium, and smooth muscle cells).59-61 Particularly, hESC-derived
cardiomyocytes exhibit the morphology of adult cardiomyocytes with expression of
mature sarcomeric proteins and mature structural arrangement of the contractile
apparatus.23, 62-64 They also express cardiac-specific transcription factors such as Nkx2.5,
GATA-4, and MEF2C and display spontaneous beating activity with characteristic atrial,
ventricular, and nodal action potentials.62-64 The strong cardiogenic potential of ESCs and
the availability of hESC-derived cardiomyocytes have motivated research into their
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effects in the treatment of heart failure in preclinical models via replacement of lost
contractile cells.
Menard et al. first reported that cardiac-committed mouse ESCs, transplanted into
infarcted sheep myocardium, engrafted and differentiated into cardiomyocytes and
improved LV function.65 Similarly, using hESC-derived cardiomyocytes, Caspi et al.66
and Cai et al.67 reported formation of stable cardiomyocyte grafts, attenuated LV
remodeling, and improvement in LV systolic function in rat models with old myocardial
infarction (MI) (although in the latter study they caused formation of teratomas). More
recently, studies reporting the use of hESC-derived cardiomyocytes (hESC-CMs) in
chronic animal models of ischemic cardiomyopathy in other large animals, including
non-human primates (specifically macaques)68, focused specifically on aspects of
engraftment, functional integration, and electrophysiological behavior of transplanted
ESC-derived cardiomyocytes in injured myocardium. In guinea pig models, Shiba and
colleagues observed re-muscularization with human myocardium which occupied
approximately 8% of the scar area. While vehicle and non-cardiac control cell groups
demonstrated progressive LV dilatation and fractional shortening deterioration, ESC-CM
recipients demonstrated sustained fractional shortening and displayed overall superior
fractional shortening relative to controls.69 In addition to improved cardiac function,
animals transplanted with ESC-CMs also exhibited reduced occurrences of both
spontaneous and induced ventricular tachycardic events. Utilizing a genetically encoded
calcium sensor (GCaMP3), the activity of hESC-CM grafted cells was tracked in vivo
suggesting successful electromechanical integration of grafted cells with host
myocardium; however, graft-host coupling in injured hearts was notably heterogeneous.69
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Similar results were observed in a later study employing hESC-CMs in a chronic nonhuman primate model of ischemic cardiomyopathy.68 Here, an unprecedented number of
hESC-CMs (1 billion) were delivered intramyocardially to macaques 2 weeks following
ischemia-reperfusion injury. According to the authors, hearts of hESC-CM recipient
monkeys demonstrated significant re-muscularization of infarct regions which ranged
from 0.7 to 5.3% (an average of 3% at 4 weeks and 1% at 12 weeks), comprising
approximately 40% of the infarct volume.68 Despite the fact that hESC-CMs assumed
only an immature phenotype, electromechanical junctions were evident among hESCCMs and host myocytes shortly after engraftment (2 weeks). The authors showed
evidence of electromechanical coupling whereby hESC-CMs exhibited regular calcium
transients that synchronized with host electrocardiograms. However, contrary to the
guinea pig model where hESC-CMs afforded protection against arrhythmias69, increased
incidence of ventricular arrhythmias was noted in primate that was given hESC-CMs.68
Strong objections to the validity and applicability of the study by Chong et al.68
were recently published. In a commentary, Anderson and colleagues highlight notable
issues of i.) small number of animals studied; ii.) small size of infarcts; iii.) a lack of
infarct size reduction compared to controls in the setting of claims of hESC-CM induced
remuscularization; iv.) possible off target effects of the zinc finger nuclease methodology
used for gene targeting of the Ca2+ indicator GCaMP3 that was utilized to assess
electrical coupling; v.) a lack of assessment of cardiac functional parameters or electrical
properties; vi.) increased prevalence of cardiac arrhythmias resulting from hESC-CM
administration; vii.) a lack of long term follow-up to assess true myocyte regeneration
which is characterized by permanent survival and terminal differentiation of engrafted
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electrically coupled cells; viii.) a lack of sufficient assessment of teratogenicity of hESCCMs given that hESC-derived cells are intrinsically heterogeneous, and one cannot
guarantee that no cells remain in an undifferentiated, pluripotent state and may therefore
give rise to malignancies.70 Given the plethora of concerns70, 71, the use of such hESCCMs in humans and the conclusions of Chong et al regarding the utility of hESC-CMs in
treating ischemic cardiomyopathy are untenable. Clear objections to the use of ESCs and
ESC-derived cells have been made.71
Despite the well-documented capacity of ESCs for cardiac differentiation, both
ethical and biological concerns have prevented their use as a treatment modality in
human patients. Specifically, because of their pluripotency and allogeneic nature,
adoptive transfer of ESCs is plagued by teratoma formation72, 73 and graft rejection72,
which essentially preclude the clinical use of these cells. In human clinical research,
tolerance for even the possibility of tumor formation is zero. Despite efforts to reduce the
probability of this occurrence by various ESC manipulations, it is cannot be completely
eliminated. Therefore, no clinical trial of ESCs in cardiovascular disease has been
conducted, as one neoplastic occurrence within a human trial subject would be sufficient
to all but halt clinical investigation of ESCs for the foreseeable future. However, the
recent emergence of induced pluripotent stem cells (vide infra), has provided an
alternative that obviates one of the two major problems inherent in ESC-based therapies –
graft rejection secondary to allogenicity.
Induced pluripotent stem cells (iPSCs)
Takahashi and Yamanaka were the first to produce a population of induced
pluripotent stem cells (iPSCs) by transducing mouse adult fibroblasts with defined
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transcription factors (OCT3/4, Sox2, c-Myc, and Klf4) (the “Yamanaka factors”).74, 75
These iPSCs express ESC surface markers and exhibit morphology and growth properties
similar to those of ESCs, essentially being reversely reprogrammed from a differentiated
cell type with finite phenotype toward an undifferentiated ESC-like cell with clonal
expansion, self-renewal, and multilineage differentiation capacities.74, 75 This discovery
ultimately resulted in a Nobel prize in 2012. Research evaluating the differentiation
capacities of iPSCs demonstrated that the cardiogenic potential of iPSCs is very similar
to that of ESCs, and that iPSC-derived cardiomyocytes possess functional properties
typical of cardiac cells, such as spontaneous beating, contractility, and ion channel
expression.76 Additionally, iPSCs have shown capacity to form endothelial and smooth
muscle cells. Thus, iPSC-derived cell lines have quickly gained momentum for cardiac
regenerative applications and multiple strategies have been employed using iPSCs and
iPSC-derived cells to treat heart failure in preclinical models.
In 2012, Gu and colleagues demonstrated the intramyocardial delivery of porcine
iPSC-derived endothelial cells (piPSC-ECs) in murine infarct models yielded significant
improvements in cardiac function via paracrine-mediated promotion of
neovascularization and cardiomyocyte survival.77 Congruent with these studies, the
administration of human iPS-derived mesenchymal stem cells (iMSCs) in a murine
infarct model was shown to mitigate ventricular remodeling and preserve myocardial
strain via paracrine-mediated promotion of neovascularization and parenchymal/stromal
cell integration in infarcted regions.78 Thus, while iPS are heralded for their
developmental potential, studies such as these suggest their salubrious effects on cardiac
function are largely mediated through paracrine signaling mechanisms and not direct
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functional integration with preexisting cardiac cell types. Such principles have been
mirrored in swine models of ischemia-reperfusion injury.79, 80 In said studies, human ESderived vascular cells (hESC-VCs) were epicardially delivered via a fibrin patch. Patchenhanced delivery of hESC-VCs ameliorated contractile dysfunction and LV wall stress,
as well improved myocardial perfusion in border zone regions. Concomitantly, hESCVC delivery promoted the recruitment of endogenous c-kit+ cells to infarct zones.
Further, cardiac improvements were correlated with enhanced myocardial energetics
assessed via in vivo 31P magnetic resonance spectroscopy-2-dimensional chemical shift
imaging.79 Shortly thereafter, a similar study was performed by the same group utilizing
vascular cells derived from human iPSCs (hiPSC-VCs).80 Patch-enhanced delivery of
hiPSC-VCs in a swine model of ischemia-reperfusion injury ameliorated ventricular
structural and functional abnormalities, reduced infarct size, enhanced vascular density
and border zone perfusion, as well as promoted the mobilization of endogenous c-kit+
cells to the injury site. These combined effects had pronounced consequences on border
zone physiology resulting in enhanced ATP turnover rates and improved contractility.
The ability of ESC/iPSC-derived vascular cells alone to enhance myocardial
bioenergetics, border zone contractility, and ventricular function in the face of acute
injury was startling and left investigators wondering whether the introduction of
additional cardiac cell types sourced from totipotent precursors would have an even
greater impact on infarct dynamics and myocardial physiology following injury. This
was addressed in the most recent iPSC related study from the Zhang laboratory.81 Here,
human iPSC-derived cardiomyocytes (CM), endothelial cells (EC), and smooth muscle
cells (SMC) (totaling 6 million; 2 million per cell type) ere simultaneously administered
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intramyocardially in a swine ischemia-reperfusion injury model. Cells were delivered in
combination with a 3D fibrin patch infused with insulin growth factor (IGF)-encapsulated
microspheres. The results of this study showed improvements in ventricular function,
infarct size, ventricular wall stress, vasculogenesis, and myocardial metabolism. Further
tri-lineage cell transplantation revealed integration of cells into host myocardial tissues,
arterioles, and capillaries; the quantity of surviving transplanted cells was substantially
greater when used in conjunction with the IGF-infused fibrin patch. Just like what was
suggested in previous studies utilizing ESC/iPSC-derived cell types, the molecular basis
of the observed improvements in cardiac function and arteriole density, following their
transplantation in infarct models, was credited to multiple paracrine mechanisms which
could promote cardiomyocyte survival, neoangiogenesis, and cardiac repair.81
Although iPSCs hold great promise for cardiac regeneration, the transcription
factors used to generate these cells (c-Myc, Oct4, and Klf4) are known oncogenes that
may induce neoplastic transformation and tumor formation. Newer methods that involve
only transient expression of the reprogramming factors rather than permanent over
expression may circumvent this problem.82 Still, other problems with iPSCs include the
extremely low efficiency of iPSC generation and the variability from one cell line to
another due to issues such as viral transfection efficiency.83 Technical aspects of these
phenomena remain outside the scope of the present report. However, given the rapidity
in which the technology in this field is evolving, it is possible that these hurdles will soon
be overcome and iPSC-based approaches will become applicable for therapeutic use in
the treatment of heart failure; at present, however, iPSCs have not proven ready for
clinical application. Accordingly, alternative approaches to ESC-(vide supra) and iPSC-
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based therapies continue to be explored using autologous and allogeneic postnatal
multipotent progenitors.

Cell based therapies for heart failure: Cardiac cell populations
Brief synopsis of fetal cardiomyogenesis and known cardiac progenitors
The heart is the first functional organ formed during embryonic development,
with cardiac progenitors specified in early gastrulation. Three spatially and temporally
distinct cardiac precursors have been identified by lineage tracing experiments in
embryonic development: cardiac mesodermal cells, proepicardial cells, and cardiac
neural crest cells. These individual lineages have been established to give rise not only to
specific cell types but also to regions of the mature heart.84-86 Understanding the
specification of these lineages in forming the mature heart is crucial if insights into the
residual progenitors’ capacity to contribute to the contractile, vascular, and interstitial
compartments, as well as response to injury, are to be gained. A brief synopsis of
embryonic cardiac development is provided below.
Within the primitive streak, time-dependent differential co-expression of vascular
endothelial growth factor receptor 2 (VEGR2, KDR, Flk-1) allows the divergence of
hematopoietic and peripheral vasculature progenitors from the cardiovascular progenitors
that give rise to the heart and central portions of the great vessels84, 85, 87-89. The latter are
designated by up-regulation of the T-box transcription factors Eomesodermin (Eomes)
and mesoderm posterior 1 (Mesp1). These Mesp1+/Eomes+/KDR+ progenitors give rise
to cardiac mesodermal cells that create the first and second heart fields (FHF, SHF) with
thin endocardium and the proepicardium (PE)84, 85, 87-92. Cooperatively, these mesodermal
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progenitors and their progeny form the near entirety of the adult heart. The ectodermal
originating cardiac neural crest cells also contribute to fetal cardiomyogenesis, but their
contributions to the contractile compartment are thought to be minimal and, therefore, are
not covered in this review.93-95
FHF progenitors in the cardiac crescent are exposed to local cytokines and growth
factors, which induce differentiation and up-regulation of essential cardiac regulators
such as Nkx2.5, Tbx5, and GATA4, among others. These transcription factors induce
commitment to myocyte lineage and sarcomeric protein expression.84, 85, 91, 92 Progenitor
tracking and lineage tracing studies have shown that the progeny of the FHF eventually
gives rise to the myocytes and some smooth muscle cells that predominantly make up the
left ventricle and the two atria. The endocardium may also arise from FHF progenitors as
early simultaneous development is observed to form the primitive heart tube, although
efforts are ongoing to further delineate early divergence of these two fields from one or
more upstream progenitors.84, 85, 87, 93, 94, 96, 97 Subsequent to FHF commitment and
formation of the primitive heart tube, the SHF progenitors, identified by the expression of
Isl-1, Nkx2.5, and KDR, begin to proliferate and migrate, undergoing commitment and
differentiation under the influence of local FGF, BMP, and Wnt signaling. SHF
progenitors have been shown to generate myocytes, some smooth muscle, and some
endothelial constituents of the right ventricle and ventricular outflow tract.84, 85, 90, 98
Importantly, these Isl-1+ progenitors have been found to lack c-kit and Sca-196, 99, 100, thus
likely excluding this compartment as a source of residual myogenic progenitors having a
c-kit+ phenotype.
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At this stage of cardiac development, the myocardium of the first and second
heart fields, possessing only a thin endocardial lining within the contorting primitive
heart tube is essentially naked, lacking adventitia, perforating vasculature, or surrounding
epicardium.84, 85, 101 These constituents have been traced to arise from distinct
proepicardial progenitor populations that express the transcription factors Wilms’ tumor
protein (Wt1) and Tbx-1884-86, 93, 94, 102, largely giving rise to adventitial and smooth
muscle lineages, as well as Scleraxis (Scx) and Semaphorin3D (Sema3D), giving rise to
adventitia and some vascular endothelium not of endocardial origin.103 Some of these
proepicardial progenitors have been found within endocardial cushions, areas well known
to be formed by early endocardial progenitors. This co-localization indicates that these
two fields undergo intermigration, essentially cooperating to form the mature structures
of the atrioventricular (AV) valves and cardiac septa through epithelial to mesenchymal
transition (EMT).61, 104, 105 It is currently unclear whether these proepicardial populations
stem from Isl-1+/Nkx2.5+ precursors of the SHF or are separately derived lineages.
Tracing studies show that these progenitors migrate over the surface of the exposed
myocardium, derived from the first and second heart fields, and form the epicardium and
epicardium-derived cells (EPDCs). 84, 106-109 Once formation of the epicardium is
complete, epicardial cells proliferate in a direction parallel to the basement membrane
(BM), resulting in thickening of the epicardial lining, or perpendicular to the BM,
undergoing epithelial to mesenchymal transition beginning around E12.5-13.5.
Ultimately, penetrating mesenchymally-transitioned EPDCs, which populate the
subepicardial region, migrate inward to form the coronary plexus (which later becomes
the coronary vasculature, with contributions of endocardium-derived endothelial cells and
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cardiac adventitial fibroblasts.84-86, 98, 104 Additionally, the epicardium and EPDCs are
involved in septation and function to stimulate myocardial growth and myocyte division,
specifically to aid formation of compact myocardium. Endocardium-derived adventitia
aids in forming the inner trabecular myocardium.60
It has recently been suggested that EPDCs may generate cardiomyocytes in fetal
development, but this is currently unresolved. Questions have been raised regarding the
specificity of the initial model that used Tbx-18 for in vivo tracing of EPDCs.110, 111
However, similar subsequent evaluation of EPDCs by Zhou et al using WT1 also
suggested that EPDCs can in fact contribute to mature cardiomyocytes during fetal
cardiogenesis although this was rare.109 The same group also performed tracing studies
of WT1+ epicardial cells in adult mice but did not find that these cells contribute to
cardiomyocytes or endothelium after infarction; lineage commitment after ischemic
injury-induced epicardial activation was primarily limited to smooth muscle and
adventitial cells.109 Importantly, the study did observe that epicardial activation did occur
as a result of ischemic injury, leading to proliferation and migration of EPDCs into the
damaged myocardium in a reparative role. However, the aforementioned findings would
support the concept that the differentiation capacity of WT1+ epicardial cells that persists
into adulthood is less than that present in fetal development, because a more limited
lineage commitment, restricted almost entirely to non-myocytes, was seen in adult
mice.109 Scx/Sema3D+ cells were found to be a distinct population of proepicardial cells
having only 33% overlapping co-expression of either WT1 or Tbx-18. Scx/Sema3D+
cells were found to give rise predominantly to coronary endothelial cells and adventitial
cells with some additional contributions to smooth muscle, and rarely cardiomyocytes in
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the embryonic heart.103 This disproportionally low magnitude of cardiomyogenic
potential mirrors that observed by the Zhou et al tracing study of WT1+ cells.109, 112
Although initial studies in zebrafish suggested that activation of epicardial progenitors
was responsible for cardiomyocyte replacement after injury, more recent work has shown
that they act by inducing division of existing cardiomyocytes; epicardial cells were traced
to give rise only to non-myocyte lineages in that model.86, 103, 113-116 The current
consensus is that the direct contribution of EPDCs to the myocardium is minimal and that
cardiomyocyte differentiation is a rarity among EPDCs, at least in the postnatal heart.86
Recent studies of the origin of the endocardium, its formation, and its eventual
contribution to mature cardiac lineages have found that its proportional contributions to
mature lineages is similar to that attributed to proepicardium-derived cells. The
endocardium arises very early in cardiac embryogenesis, simultaneously with the FHF,
likely stemming from a common progenitor. Endocardial cells have been shown to arise
from Bry+/Flk-1+/Nkx2.5+ progenitors forming the primitive heart tube.101 These
progenitors are distinct from hemangioblast precursors and are identified by a distinct
expression profile (an E-cadherinlow, Flk1low, NF-ATc1+ phenotype).117 NF-ATc1 was
found to be expressed exclusively in endocardium, providing a lineage specific marker
that enables differentiation of the endocardium from other endothelial cell types.118
Tracing and knockout studies performed by de la Pompa et al. demonstrated that
endocardial cells not only contribute to a subset of cardiac endothelial cells, but also are
integral to cardiac cushion formation, valvulogenesis, septation of the atria, ventricles,
and aortopulmonary trunks, as well as to guiding myocardial trabeculation.101, 118 These
processes are governed by EMT of endocardial cells (similar with respect to mechanism
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and signaling pathways to that widely recognized to occur in EPDCs) that precipitates
differential commitment to various mature cardiac lineages.104 The complex regulatory
pathways underlying EMT of endocardial cells (as well as that of EPDCs) involve Notch,
TGF beta superfamilies, SMADs, Wnt/β-catenin, and bone morphogenic proteins
(BMPs) signaling among others. Comprehensive reviews of these signaling cascades
have recently been published.104 NF-ATc1 null mice, which lacked endocardium and
therefore endocardial contributions to cardiac morphogenesis, showed marked
abnormalities in trunkal, valvular and septal formation which were ultimately
embryonically lethal. Interestingly, myocardial, adventitial, and most vascular
endothelial compartments were found to be unaffected indicating that the endocardium
does not contribute significantly to these compartments.101 Similarly, studies in Tie1/TEK(Tie2) null mice showed early embryonic lethality with impairment not only of
endocardium formation but also of valvular and septal derivatives, and a lack of
myocardial trabeculation.119 Interestingly, there was no impairment of early
cardiomyocyte formation.119 It remains unclear, however, whether there are
subpopulations of endocardial cells not defined by NF-ATc1 or Tie1/TEK expression that
may contribute to these lineages.
Cardiosphere-derived cells
Cardiospheres were first described by Messina et al. in 2004.120 Using atrial or
ventricular human biopsy samples and murine hearts, these authors identified a
population of cells that grew as self-adherent clusters and showed ability to differentiate
into cardiomyocytes, endothelial cells, and smooth muscle cells. Messina et al. termed
these clusters “cardiospheres”. Cardiospheres were also able to be obtained from
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percutaneous endomyocardial biopsy specimens. Cardiospheres were plated and
expanded in vitro to yield cardiosphere-derived cells (CDCs)121. Cardiospheres and
CDCs are a heterogeneous mixture of many different cell types, including cells that
express endothelial (KDR [human]/ flk-1 [mouse], CD31), stem cell (CD34, c-kit, Sca-1),
and mesenchymal (CD105, CD90) antigenic markers.120 Importantly, the precursor cell(s)
that gives rise to cells capable of cardiosphere generation and CDCs has yet to be
identified. CDCs were reported to differentiate into electrically stable cardiomyocytes in
vitro and, to promote cardiac regeneration and improved cardiac function when injected
into a murine infarct model.121 Johnston et al. reported that intracoronary delivery of
human CDCs in pigs with old MI resulted in cardiac regeneration, reduction in “relative”
infarct size, abrogation of adverse LV remodeling, and improvement in ejection
fraction.122
One clinical trial has been conducted to date using CDCs in patients with ICM.
The safety and efficacy of direct intramyocardial injection of CDCs and cardiospheres
were compared in a porcine model of ICM. Although CDCs and cardiospheres had
equivalent effects on ejection fraction, the latter proved superior in improving
hemodynamics, regional cardiac function, and reducing ventricular remodeling. This
preclinical work was translated by Makkar et al. in a phase I, randomized trial
(CADUCEUS) in patients with a recent myocardial infarction and LVEF≤45% but
≥25%.123 Patients received an intracoronary infusion of escalating doses of autologous
CDCs (12.5, 17.3, or 25 x 106 cells) or vehicle control with standard medical therapy.
CDC-treated patients exhibited a 42% reduction in scar size (from 24% to 12% of the left
ventricle), associated with an increase in viable tissue and regional systolic wall
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thickening in the infarcted region. CDC therapy failed to increase ejection fraction,
reduce LV volumes, or improve heart failure functional class or quality of life as assessed
by standard questionnaire.123 Further studies utilizing CDCs/cardiospheres are currently
underway.
C-kit positive cardiac progenitor cells
The observation of sex mismatched cardiomyocytes of recipient origin in donor
hearts led to the conclusion that cells circulating in the peripheral blood, likely
originating from the bone marrow, engraft and transdifferentiate into integrated,
functional cardiomyocytes.124 Several studies of unfractionated bone marrow and bone
marrow-derived mesenchymal stem cells (MSCs) have shown beneficial effects, but
differentiation of these cells into cardiomyocytes seems unlikely125, 126; more likely
mechanisms include paracrine actions and/or cell fusion of cardiomyocytes and bone
marrow derived cells.125-127 Importantly, evidence of cardiomyocyte division, coupled
with carbon-14 labeling studies, has led to the recognition that there is cardiomyocyte
turnover in the adult heart, fueling the search for a cardiac stem cell compartment that is
innately endowed with cardiomyogenic potential.128, 129
In 2003, Beltrami et al. reported the discovery of resident c-kit+ cardiac cells
(CSCs) that were able to give rise to all cardiac lineages including cardiomyocytes.130
The initial discovery was based on the presence of the c-kit receptor on hematopoietic
progenitors; it was postulated that the presence of c-kit may identify a cardiac population
of myocardial progenitors similar to that of the hematopoietic compartment.130 In fact,
this is what Beltrami and colleagues found. They observed co-localization of c-kit with
Nxk2.5, GATA-4 (transcription factors active in cardiomyogenesis), and Ki-67 (a nuclear
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antigen associated with cell division) but not with mature sarcomeric proteins, suggesting
a precursor cell, i.e., a proliferating cell that is apparently committed to cardiac lineage
but lacks a mature phenotype. The absence of the hematopoietic markers CD34 and
CD45 indicated that the cells were not immediately from the bone marrow, and were
therefore intrinsic to the heart. Therefore, it was concluded that the c-kit+ cardiac cells
were derived from the embryonic cardiac compartments that give rise to the adult
myocardium.130
Since the c-kit receptor plays an important role in prosurvival and proproliferative signaling, the c-kit+ phenotype may represent an intermediate progenitor,
derived from an upstream c-kit-, more undifferentiated cardiac progenitor in which c-kit
expression increases in conjunction with cell cycle entry and differentiation. This
remains a conjecture, however, as direct observation of this is currently lacking, although
it is extremely probable. Beltrami and colleagues also alluded to this possible hierarchy
in their report of c-kit+ cardiac cells, which were found to largely coexpress Nkx2.5.130
This postulated upstream resident progenitor in the heart has yet to be identified.
Evidence of a similar phenotypic progression, now widely accepted, was observed in the
bone marrow with the isolation in 2003 of c-kit- hematopoietic stem cells, which were
found to give rise to c-kit+ intermediate phenotypes that ultimately were able to
reconstitute all mature hematopoietic lineages.131
Over the last decade, conflicting results have been obtained with respect to the
cardiomyogenic ability of c-kit+ cardiac cells. In vitro, differentiation of cells from adult
hearts into mature beating cardiomyocytes has not been reported although expression of
some sarcomeric proteins has been found 130, 132, 133. In vivo, reports of adult

25

cardiomyocyte formation 130, 132, 134-138 have not been reproduced by several other labs 9,
10, 139-146

. Whether this discrepancy is caused by differences in source (fetal and/or

neonatal cells vs. adult cells), or culture, isolation, or expansion conditions remains to be
determined.
Nevertheless, the ability of human and rodent c-kit+ cardiac progenitor cells to
ameliorate left ventricular dysfunction and pathologic remodeling and promote
regeneration has been repeatedly demonstrated by several laboratories in various
preclinical animal models of acute myocardial infarction.132, 141-143, 145-147 Intramyocardial
injection of c-kit+ cardiac progenitor cells within the border zones of an infarct 20 days
after a permanent coronary occlusion in rats resulted in attenuation of LV dilation and
preservation of LV function.147 Additionally, Tang et al.145 demonstrated that
administration of CPCs is effective in regenerating cardiac tissue and alleviating postinfarction LV remodeling and dysfunction when these cells are infused intracoronarily in
the setting of chronic ICM produced by a temporary coronary occlusion followed by
reperfusion. One month after coronary occlusion/reperfusion, rats received an
intracoronary infusion of vehicle or EGFP-labeled cells. Notably, CPC-treated rats
exhibited more viable myocardium in the risk region, less fibrosis in the noninfarcted
region, and improved LV function. Interestingly, the number of EGFP+ cells expressing
markers of cardiogenic commitment was too small to account for the augmentation of LV
function (EGFP+ cells accounted for only 2.6±1.1% of the region at risk and 1.1±0.4% in
the noninfarcted region). In short, CPCs did not survive, engraft, or differentiate into
mature cardiac phenotypes within the myocardium.145 These observations suggest that the
important mechanism whereby CPCs generate their beneficial effects was likely a
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paracrine action of donor cells on the endogenous myocardium with secretion of
cytokines/growth factors locally. Also, induction of endogenous CPC proliferated and
differentiated into adult cardiac cells was indicated by the finding that the pool of
endogenous CPCs expanded to a greater degree in CPC-treated than in control rats.145
Similar results were obtained with intracoronary infusion of autologous CPCs into a
large, clinically-relevant porcine model of ICM in which pigs underwent a 90-min
coronary occlusion followed by reperfusion.139 Intracoronarily delivered stem cells to the
infarct-related artery using the stop-flow technique produced an increase in ejection
fraction and systolic thickening fraction in the infarcted left ventricular wall, as well as a
decrease in left ventricular end-diastolic pressure (LVEDP) and an increase in left
ventricular dP/dtmax in pigs with old infarcts.139 The encouraging results of these studies
of intracoronary CSC infusion in the setting of an old MI laid the groundwork for
SCIPIO, the first clinical trial of c-kit+ CPCs.139, 148
Because of encouraging results of both preclinical and clinical studies, c-kit+
cardiac progenitor cells have emerged as one of the most attractive cell types for
therapeutic application. At the preclinical level, numerous studies conducted by many
independent laboratories in a wide variety of animal models of ischemic cardiomyopathy
have consistently documented salubrious effect of exogenous c-kit+ cardiac progenitor
cells on left ventricular function and structure, including evidence of regeneration of dead
myocardium. At the clinical level, a small phase I study (the SCIPIO trial) has
documented the safety of autologous c-kit+ cardiac cell administration in patients with
ischemic heart failure.148 Although SCIPIO was not designed to assess efficacy, its results
suggest that c-kit+ cells may impart beneficial effects on left ventricular function, quality
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of life, functional class, and infarct size, providing a rationale for larger trials aimed at
determining efficacy. Such trials will undoubtedly utilize larger dose(s) of cells than was
administered to patients within the SCIPIO trial (just 1 million).148 However, no studies
have evaluated the safety of escalating doses of cells delivered intracoronarily, which
could have adverse effects such as embolization and resultant myocardial ischemia. Such
an event could be catastrophic to already structurally and functionally compromised
hearts damaged from prior infarction.

Dissertation Research: Overview
With the work contained in this dissertation, in addition to providing the above
broad review of clinically relevant past and present cell based therapeutic approaches, I
sought to expand current modalities of cell based therapies in the treatment of ischemic
heart failure through discovery and evaluation of novel cardiac cell types and expansion
of applications of existing approaches using intracoronarily delivered c-kit+ cardiac
progenitor cells. I evaluated the safety of larger doses of intracoronarily administered ckit+ cardiac progenitor cells as well as their intracardiac retention post intracoronary
delivery within a clinically relevant porcine model of chronic ischemic cardiomyopathy.
Such data are immediately relevant and translatable to the design of human clinical trials
utilizing c-kit+ cardiac progenitor cells (CPCs). Data demonstrating this fact are included
in two recently published peer reviewed publications and were also presented at the 2015
Scientific Sessions of the American Heart Association annual meeting by Dr. Roberto
Bolli. These data directly aided in the design of the phase I/II clinical trial CONCERT
that has recently initiated enrollment. In addition, I provide data related to the discovery,
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characterization, and therapeutic potential of a novel population of postnatal cardiac
progenitors, possibly hierarchically related to c-kit+ cardiac progenitor cells, that
residually express embryonic stem cell associated antigens and are not yet described
within the literature. Accordingly, some of the data represented herein remain
unpublished and highly confidential. These data will be prefaced in much more detail
throughout the manuscript (vide infra).
Hypothesis and Research Aims
Hypothesis:
A. The present research seeks to empirically examine the safety of high dose
intracoronary administration of cardiac stem cells within a porcine model to provide
relevant information to the design of future clinical trials of cell-based therapy for
myocardial repair. B. Additionally, the research seeks test the validity of and provide
rational for or against the use of the Stop-flow technique during intracoronary infusion
based on the dogma that Stop-flow is necessary for improved cardiac retention of cells
post infusion by abrogation of downstream cellular washout. C. Finally, the research
seeks to ascertain whether additional populations of cardiac progenitors that may express
stage-specific embryonic stem cell associated antigens (SSEAs), previously alluded to
exist within the rodent myocardium), may be found within the human heart. Could such
cells be isolated from the human heart, expanded in vitro, and utilized for myocardial
repair after ischemic injury thus providing an new target cell type to be utilized in future
human clinical trials in patients with ischemic heart failure.
Aims:
1. Measure and compare intramyocardial retention of intracoronarily infused
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CPCs with vs without utilization of coronary stop-flow conditions via radiolabel
tracking of cell distribution.
2. Determine safety of high dose intracoronary CPC administration via
assessment of myocardial damage/injury via measurement of temporal cardiac
biomarker release as well as functional parameters measured by 2D
echocardiography over 1 month following intracoronary infusion. Additionally,
determine safety of high dose CPC administration related to clinical indices of
systemic organ function, namely hepatic and renal function.
3. In clinically relevant human right atrial appendage samples obtained from
open heart surgeries, determine if there are intramyocardial populations
expressing Stage-specific Embryonic Antigens-3&4 that may indicate existence
of a yet undescribed cardiac progenitor pool. Additionally, characterize this
population and ascertain in vitro differentiation capacity to possibly relate it to
one or more embryonic cardiomyogenic compartments. Finally, determine
reparative potential of such cells in a model of ischemic cardiomyopathy.

Hypothesis and Aims Summary:
I hypothesized that higher doses of c-kit+ CPCs delivered intracoronarily in pigs
with prior infarctions would be safe and not result in myocardial damage via embolic
phenomena. Furthermore, I hypothesized that intracardiac retention of intracoronarily
delivered c-kit+ CPCs would be very low, indicating that the salubrious effects observed
in prior studies were imparted by only a small fraction of the administered dose. In aim
1, I utilized indium-111 radiolabeling and nuclear gamma camera imaging to localized
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the anatomic site of cell deposition/retention and quantify the intracardiac retention of
cells 24 h post administration to confirm that only a small fraction of cells are actually
retained within the heart and are responsible for beneficial effects irrespective of any
attempt to maximize cell retention by coronary stop-flow. In aim 2, , I demonstrated that
there was no release of cardiac biomarkers or decline in cardiac function indicative of
myocardial injury after intracoronary administration of 20 million c-kit+ CPCs thus
confirming safety of doses higher than that previously using in clinical trials to date.

A

comprehensive review of the literature related to the possible origins of c-kit+ CPCs led
me to hypothesize that there were yet unidentified upstream progenitors within the heart
that may give rise to c-kit positive intermediate phenotypes during differentiation. I
hypothesized that these primitive cells may retain characteristics typical of other
undifferentiated primitive cells, specifically embryonic stem cell associated antigens that
may aid in identification and isolation. In aim 3, I successfully identified cardiac cells
expressing stage-specific embryonic antigen (SSEA) – 3, demonstrating a partial
overlapping phenotype with c-kit expression in vivo, and that SSEA-3+ cells possess
therapeutic utility in the treatment of ischemic cardiomyopathy after isolation and in vitro
expansion.
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CHAPTER II
EFFECT OF THE STOP-FLOW TECHNIQUE ON CARDIAC RETENTION OF C-KIT
POSITIVE HUMAN CARDIAC PROGENITOR CELLS AFTER INTRACORONARY
INFUSION IN A PORCINE MODEL OF CHRONIC ISCHEMIC
CARDIOMYOPATHY

Introduction
Since their initial discovery and characterization130, c-kit+ (c-kitpos) cardiac
progenitor cells (CPCs) have emerged as a promising modality in the treatment of
ischemic cardiomyopathy. Preclinical studies conducted over the last decade have
reproducibly demonstrated the capacity of in vitro expanded c-kitpos cardiac cells to
induce myocardial repair and functional recovery.8 These observations led to the Cardiac
Stem Cell Infusion in Patients with Ischemic CardiOmyopathy (SCIPIO) phase I clinical
trial, which demonstrated the safety and feasibility of intracoronary delivery of c-kitpos
CPCs in humans.148 Recently, the safety of even larger doses (up to 20 million in vitro
expanded c-kitpos CPCs) has been demonstrated in a porcine model and will be discussed
later (vide infra).
In SCIPIO148, as well as in almost every trial of intracoronary cell infusion
performed to date, the cells were delivered with the stop-flow technique149-151; that is, an
intracoronary balloon was inflated to stop flow within the coronary artery and prevent
rapid wash out of the cells, thus, in theory, promoting greater cell retention by enhancing
vascular adhesion and extravasation into the surrounding myocardium. This approach is
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being used in most ongoing and planned clinical trials in which cells are infused
intracoronarily. Although theoretically attractive, however, the stop-flow technique has
not been shown to be superior to non-occlusive cell delivery in terms of cell product
retention. The stop-flow technique is potentially hazardous152, 153, and therefore
constitutes an impediment to the widespread use of cell therapy in patients with
cardiovascular disease, particularly when, as is often the case in chronic ischemic
cardiomyopathy, the culprit coronary arteries targeted for cell delivery are not stented.
Manipulation of a non-stented coronary artery with an intraluminal balloon under
pressure carries a significant risk of vascular damage, coronary artery dissection, and
even life-threatening arterial perforation and rupture.152 In addition, the interruption of
coronary flow may elicit myocardial injury, either directly from epicardial coronary
artery occlusion or by distal microembolization of dislodged atherosclerotic plaque
material154, 155, and may cause arrhythmias in already dysfunctional hearts. Again, this
issue is particularly relevant to patients with ischemic cardiomyopathy, whose targeted
coronary arteries or bypass grafts are often not protected by stents.
Given the seriousness of the aforementioned complications, objective evidence of
improved cell retention is essential to justify subjecting patients to increased procedural
risks in future clinical trials involving intracoronary administration of cell-based
products. However, as mentioned above, despite the widespread assumption that the stopflow technique promotes improved extravasation and cardiac retention of cells, no studies
have evaluated the utility of the technique using c-kitpos CPCs or any cardiac-derived cell.
Accordingly, we addressed this issue in a clinically relevant porcine model of ischemic
cardiomyopathy in which we measured the cardiac retention of 10 million indium-111
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oxine radiolabeled c-kitpos CPCs infused with or without the stop-flow technique.
Additionally, this study allows determination of the effective intracardiac retention of
CPCs that resulted in the salubrious effects of intracoronarily delivered CPCs observed in
the SCIPIO trial.148
Methods
Ethics Statement
This study was carried out in strict accordance with the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health and the guidelines of the
Animal Care and Use Committee of the University of Louisville (KY) School of
Medicine following the guidelines set forth by the 1996 Guide for the Care and Use of
Laboratory Animals.. The protocol was approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Louisville (IACUC number: 12114).
The experimental protocol is illustrated in Fig. 1.
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Figure 1. Stop-flow study experimental protocol and timeline.
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Human c-kitpos CSC isolation and flow cytometry
Isolation, immunomagnetic selection, and flow cytometric analysis of c-kitpos
hCPCs was performed as previously described.139, 156 Briefly, human right atrial
appendage specimens (RAAs) were obtained with Jewish Hospital Institutional Review
Board (IRB) approval (IRB number 07.0062) from patients undergoing open-heart, on
pump, coronary artery bypass surgery at Jewish Hospital in Louisville, Kentucky. All
patients were between 40 and 80 years of age, so as to approximate the ages of patients in
the recently conducted SCIPIO trial.148 RAAs were washed several times with PBS and
were minced to obtain fragments < 1mm3. The tissue fragments were underwent
multiple rounds of enzymatic digestion. Isolated cells were plated in a 6-well plate for
passage 0 initial expansion. Passage 1 cells were sorted for c-kit with anti-CD117
Miltenyi microbeads and a Miltenyi magnetic sorting apparatus per manufacturer’s
specifications. Positively selected cells were expanded exponentially over 3-4 additional
passages to obtain 2-3 x 107 cells per patient. Multiple patients’ cells were pooled to
obtain a uniform cell product that was radiolabeled and infused intracoronarily into pigs.
Cells were assessed for c-kit positivity by flow cytometric analysis at passage 3 after
fixation and labeling with c-terminal specific Santa Cruz C19 rabbit polyclonal IgG antihuman c-kit antibody and secondary antibody, a FITC or APC conjugated Invitrogen
donkey anti-rabbit IgG versus isotype control using a BD LSR flow cytometer. BD LSR
DIVA software was used for final analysis of c-kit positivity.
Cell product generation and indium-111 oxine radiolabeling
In vitro expanded c-kitpos CPCs were trypsinized and washed with sterile PBS and
resuspended in Plasmalyte-A solution with ~750 µCi indum-111 oxine, purchased from
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Cardinal Health, Nuclear Pharmacy Services in Louisville, Kentucky, for 20 min at 37°C
with 5% CO2. A Capintec CRC-15R Radioisotope Dose Calibrator was used to conduct
all radioactivity measurements. After 20 min, the cells were washed twice in 10 mL of
cold Plasmalyte-A to remove unbound radioisotope. The cells were resuspended in 1-2
mL of Plasmalyte-A for final cell count and viability by hemocytometer and Trypan blue.
A final radioactivity measurement was made to assess percent radiolabeling efficiency.
After the intracoronary infusions were completed, tubes, catheters, plastic ware,
and other materials that had come into contact with the radiolabeled cells were taken back
to the dose calibrator for radioactivity measurement. The residual radioactivity was
subtracted from that of the labeled cell product to obtain the radioactivity of the cell
product that was administered intracoronarily. This number was recorded and utilized for
all subsequent calculations of cardiac cellular retention.
Radiolabeling efficiency
Radiolabeling efficiency was defined as the ratio between the final radioactivity
of the cell product prior to infusion and the initial dose of indium-111 to which the cells
were exposed.
Adjustments for diffusive loss of Indium-111 oxine over the 24 h follow-up and
calculation of cardiac radioactivity
Diffusion of unbound indium-111 oxine out of labeled cells continues over time,
and this may lead to potential underestimation of cell retention. Similar observations
have been made in prior studies.157
Experiments were performed in triplicate. Ten million cells were radiolabeled
with indium-111 oxine as described and placed in 5 mL serum-free Ham’s F12 medium
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for 24 h with periodic media changes. Media was completely changed every 4 h to
maintain a high diffusive gradient similar to that which occurred in vivo after cell
infusion. Extreme care was taken to avoid loss of cells. After 24 h, cells were
centrifuged and the cell pellet assessed for radioactivity. Diffusive loss was quantified as
percent of expected radioactivity after accounting for radioactive decay over the 24 h
incubation period. A correction factor was generated by dividing 100 by this observed
percent of theoretical maximum radioactivity, so as to account for all infused cells and
avoid underestimation of intracardiac retention at 24 h.
The radioactivity measured in all cardiac segments was adjusted according to the
correction factor (3.52) to obtain the corrected radioactivity for each cardiac tissue
specimen. All radioactivities were then summed to obtain the total radioactivity of each
heart. This total corrected cardiac radioactivity was divided by the expected maximum
radioactivity of the infusate (adjusted for time dependent decay) to obtain the percent
retention of the intracoronarily delivered indium-111 oxine labeled cell product.
Animal procedures
Female Yorkshire pigs (39.8 ± 5.2 kg, age 12-18 weeks) were sedated using a
cocktail of ketamine (20 mg/kg, i.m.) and xylazine (2 mg/kg, i.m.), intubated, and
mechanically ventilated with 100% oxygen. Anesthesia was maintained with 0.8-1.5%
isoflurane. A femoral artery cut-down was performed and an 8F arterial sheath was
placed; a 7F Hockey-stick guide catheter was advanced to the left coronary ostium. An
angioplasty balloon catheter was positioned in the left anterior descending (LAD)
coronary artery at a site distal to the first diagonal branch, after which the pigs were

38

subjected to a 90-min LAD coronary occlusion followed by reperfusion by inflation and
deflation of the balloon, respectively (Fig. ).
One to two months (45.3 ± 4.5 days) after MI, the pigs were reanesthetized. An
angioplasty balloon catheter was placed in the LAD at the site of the previous occlusion.
Indium-labeled hCSCs were administered with four infusions, each consisting of 3 ml
over 30 s, with or without concurrent 3-min balloon inflation. In the pigs with balloon
inflation, five cycles of 3-min balloon inflation/3-min deflation were performed. The aim
of the first cycle, which was performed without infusing cells, was to increase
microvascular permeability in the distal myocardium; during the following four cycles,
hCPCs were infused into the coronary artery as described above. In the pigs without
balloon inflation, hCPCs were infused four times; each infusion lasted 30 s and the four
infusions were interspaced with intervals of 5 min and 30 s (Fig. 1).
Twenty-four hours after hCPC administration, the pigs were euthanized and
various organs (heart, lung, liver, kidney and spleen) were harvested for analysis.
Immunosuppressive therapy
Pigs received 15 mg/kg/day of oral cyclosporine (Novartis) orally starting 3 days
before cell infusion and continuing until euthanasia.
Echocardiography
Echocardiograms were obtained at baseline (before the induction of infarction)
and again 30 d later (prior to radiolabeled hCPC intracoronary infusion) using an HP
SONOS 7500 ultrasound system (Philips Medical Systems) equipped with a HP 21350A
(S8) 3.0-8.0 MHz sector array ultrasound transducer. Briefly, pigs were anesthetized and
placed in the left lateral decubitus position. Temperature was kept between 37.0°C and
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37.5°C with a heating pad. The parasternal short-axis view was used to obtain 2D and Mmode images.148 Systolic and diastolic anatomic parameters were obtained from M-mode
tracings at the mid-papillary level. Digital images were analyzed off-line by a single
blinded observer using the ComPACS Review Station (version 10.5) image analysis
software (Medimatic, Las Cruces, NM 88004, USA) according to the American Society
of Echocardiography standards.158
Nuclear imaging and cardiac radioactivity measurements
Perfusion fixed porcine hearts were subjected to nuclear imaging and radioactivity
measurements. After whole heart nuclear imaging with Picker Prism 2000 XP nuclear
gamma camera, hearts were bread-loafed into five slices of equal thickness from the apex
to the base; each slice above the apex was then subdivided into three regions: right
ventricle, left ventricular free wall, and septum. The base was divided into right and left
sections. The right and left atria were sectioned and placed into independent containers.
The proximal portions of the great vessels were removed and placed together into another
container. All specimens were measured with a Capintec CRC-15R Radioisotope Dose
Calibrator and the anatomic regions were combined to create a regional distribution of
radioactivity. The radioactivity in all regions was then combined to obtain the total
radioactivity in each heart. The same dose calibrator was used throughout the study.
Statistics
Student’s t-test , one-way ANOVA, or two-way repeated measures ANOVA, as
appropriate, was employed for comparisons of echocardiographic parameters,
radioactivities, and cell retention between groups. All data are reported as means ± SEM.
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Results
Flow cytometric analysis
Flow cytometric analysis for c-kit expression was performed for seven cell lines
at early passage as described (c-kit positivity ranged from 72.6% to 90.8%). The mean ckit positivity of the cells utilized for the study as assessed by standard protocol was
81.6±7.0% compared with isotype control (Fig. 2A).
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Figure 2. C-kit positivity, cell product radioactivity, radiolabeling efficiency, cell
product viability, cell number, and diffusive loss of indium-111 oxine. A. C-kit
positivity of individual cell lines is illustrated by black bars, with mean positivity shown
in white. C-kit positivity ranged from 72.6% to 90.8% with mean c-kit positivity of
81.6±7.0%. Cell lines were combined to obtain a homogenous cell product. B. Mean
final cell product radioactivity of cells infused with continuous flow [Stop-flow (-)] or
stop-flow [Stop-flow(+)]. C. Indium labeling efficiency of cells administered with or
without stop-flow. D. Mean cell viability, assessed by Trypan blue, before (black bars)
and after (white bars) radiolabeling. E. Number of radiolabeled hCSCs in each group.
All values are mean±SEM.
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Final cell product radioactivity, labeling efficiency, cell viability, and cell number
Final radioactivity and radiolabeling efficiency were calculated for all cell
products prior to intracoronary infusion. No significant difference between cell products
was observed with regard to the final mean radioactivity (Fig. 2B) (635±74.28 µCi in the
continuous-flow group vs. 661±63.28 µCi in the stop-flow group) or mean labeling
efficiency (Fig. 2C) (81.0±8.4% in the continuous-flow group, 84.5±9.8% in the stopflow group).
Cell viability, measured by hemocytometer and Trypan blue, declined in both
groups as a result of indium-111 oxine radiolabeling. However, no significant difference
was observed in the viability of the cell products between the continuous-flow
(85.0±0.81%) and the stop-flow (83.0±0.78%) groups (Fig. 2D). Similarly, there was no
significant difference with respect to the final numbers of cells infused intracoronarily
between the continuous-flow (10.1±0.41 x 106 cells) and the stop-flow (9.83±0.25 x 106
cells) groups (Fig. 2E).
Echocardiographic analyses
Baseline left ventricular (LV) ejection fraction (EF) was not significantly different
between the continuous-flow group (74.35±4.09%) and the stop-flow group
(71.16±4.11%) (Fig. 3). At 30 days after infarction, there was a significant decline in
both the continuous-flow group (44.57±6.75%) and the stop-flow group (37.79±6.77%).
The decline in ejection fraction did not differ significantly between the continuous-flow
and stop-flow groups (P=0.49).

43

Figure 3. LV ejection fraction. Echocardiographic analyses were performed at baseline
and again 30 d after infarction prior to intracoronary radiolabeled hCSC delivery to
measure ejection fraction. Ejection fraction at 30 d after infarction was not significantly
different between groups indicating similar degree of myocardial injury and functional
decline (P=0.49).
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Nuclear imaging
Myocardial nuclear imaging was performed to visualize the distribution of
radioactivity and, indirectly, cell retention. As expected, cell (radioactivity) retention
was observed in the distribution of the mid-distal LAD within the apical, anteroseptal,
and anterolateral regions (Fig. 4).
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Figure 4. Nuclear imaging of hCSC retention. Cell retention was assessed by
radioactivity and visualized by whole heart nuclear imaging. Radioactivity was observed
in the distribution of the LAD, specifically, in the anteroseptal, anterior, and anterolateral
walls of the left ventricle. Areas of high radioactivity and cell retention are identified by
the bright orange coloration while areas with no or low radioactivity are identified by
blue/purple coloration.

46

Cardiac retention of hCSCs
Measurements of total cardiac radioactivity demonstrated that the stop-flow
technique did not result in significantly higher retention of hCPCs at 24 h compared with
the continuous-flow technique (5.41±0.80% vs. 4.87±0.62% of initial radioactivity,
respectively, P=0.61) (Fig. 5). Regional retention was also not significantly different
between stop-flow vs. continuous-flow (right ventricle: 1.60±0.30% vs. 1.02±0.15%,
respectively, P=0.12; LV septum: 1.88±0.43% vs. 1.81±0.33%, P=0.91; LV anterolateral
wall: 1.17±0.37% vs. 1.10±0.17%, P=0.87; LV apex: 0.23±0.05% vs 0.31±0.11%,
P=0.56; right atrium: 0.10±0.03% vs. 0.11±0.02%, P=0.81; left atrium: 0.10±0.02% vs.
0.12±0.03%, P=0.61; base: 0.33±0.38% vs 0.39±0.13%, P=0.71) (Fig. 5).
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Figure 5. Myocardial hCSC retention at 24 h. Illustrated is the regional distribution of
radioactivity in the continuous-flow (black) and stop-flow (white) groups. There was no
significant difference in regional or total radioactivity (cell retention) between the
continuous-flow (4.87±0.62%) and the stop-flow (5.41±0.80%) groups (P=0.61).
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CSC distribution in noncardiac tissues
In all pigs, three small samples of lung, liver, kidney, and spleen were assessed
for radioactivity. Radioactivity was highest in the lung (17.48±0.11% of initial dose),
followed by the liver (9.52±0.51 of initial dose), kidney (3.08±0.43%), and lastly spleen
(0.26±0.06%). Radioactivity was highly variable in different regions of the same organ.
Discussion
This study simultaneously addressed three fundamental questions regarding
intracoronary infusion of c-kitpos hCPCs: i) what fraction of hCPCs is retained in the heart
24 h after intracoronary infusion?, ii) what may have been the effective dose of CPCs
responsible for the indications of function benefits observed in the SCIPIO trial? and iii)
is the stop-flow technique superior to continuous-flow in promoting cardiac retention of
hCPCs? That is, is the increased risk of procedural complications associated with balloon
inflation justified by increased hCPC retention? Our results indicate that, in pigs with an
old myocardial infarction, intracoronary infusion of hCPCs without coronary occlusion is
equivalent to intracoronary delivery utilizing the stop-flow technique in terms of cardiac
hCPC retention at 24 h. It may also be reasonably inferred that ischemic preconditioning
with intermittent balloon inflation/deflation, which has been shown to confer
cardioprotective effects155, does not affect cardiac retention of CPCs, thus eliminating
this confounder in studies in which cell therapy has shown benefit when true stop-flow
was utilized in the treatment group but was withheld in the vehicle control group to
minimize risk of complication. With either method, we found that only ~4-5% of the
infused hCPCs remained in the heart 24 h after intracoronary delivery. To our
knowledge, this is the first head-to-head comparison of cardiac retention after
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intracoronary delivery of hCPCs (or any cardiac-derived cell) using continuous flow vs.
stop flow.
Previous studies have examined the retention of various stem/progenitor cell types
using various routes of administration, such as intravenous, intracoronary, and
transmyocardial injections, in clinical and preclinical models.52, 141, 159-165 However,
studies that specifically compared cell product retention under continuous-flow and stopflow conditions have been limited to bone marrow cells, and most have infused cells after
acute myocardial infarction.159, 162, 164 Doyle et al159 infused 18F-FDG-labeled BMCs
intracoronarily in pigs after acute myocardial infarction and observed that a single dose
of cells given with continuous flow was superior to repeated infusions with stop-flow
with respect to cardiac retention 1 hour later. Tussios et al164 infused indium-111 oxinelabeled BMCs intracoronarily into pigs and found no difference in cardiac retention at
both 1 h and 24 h after infusion comparing the two techniques. Perhaps of greater
relevance, Musialek et al. infused 99Tc-extametazime-labeled bone marrow CD34+ cells
in patients 6-14 days after acute myocardial infarction under continuous and stop-flow
conditions; they found equivalent cardiac retention (~ 5%) with both techniques at 36-48
h after infusion162, which is similar to the results of the present study. Our study differs
from the aforementioned preclinical studies in that we evaluated cardiac-derived cells and
used a model of old myocardial infarction (scar), which is more relevant to the clinical
use of cardiac-derived cells.
Analysis of various cardiac regions showed that there were no significant
differences in the distribution of indium-111 oxine-labeled hCPCs between the two
infusion techniques (Fig. 5). The overall retention of cells observed at 24 h (~4-5%) was
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comparable to that observed in previous preclinical and clinical investigations using a
variety of cell types.26, 52, 141, 160, 162, 163, 165-167 Therefore, intracardiac retention may be
more related to route of administration rather than cell type whether intrinsically native
heart or from extra-cardiac organs. We found a relatively high level of radioactivity in
the apical portions of the right ventricular wall (Fig. 5). This observation can be
accounted for by the fact that, in the pig, an accessory arterial branch originating from the
distal LAD supplies the apical portions of the right ventricle.168, 169 Radioactivity
measurements of noncardiac organs indicated that the highest deposition of CPCs after
intracoronary infusion is in the lungs followed by liver, kidneys, and spleen.
The specific protocol for the stop-flow technique (one 3-min occlusion without
cell infusion followed by four 3-min occlusion/3-min reperfusion cycles) was chosen
because it is the same protocol that was used in the SCIPIO trial. The infusion of
radiolabeled cells made it impossible to perform histologic analysis of the myocardium,
because of the prolonged decay period of indium-111 oxine and attendant safety
concerns. We were unable to ascertain whether remaining CPCs were adherent to walls
of the microvasculature or had extravasated into the myocardium. To verify that the
magnitude of damage produced by coronary occlusion/reperfusion was comparable
between the two groups of pigs, we assessed LV function before and 30 d after infarction
using echocardiography. Our measurements show that, 30 d after infarction, LV function
did not differ significantly between the two groups, indicating a similar severity of the
ischemic damage (Fig. 3).
The choice of the animal model was dictated by considerations related to clinical
relevance. Clinically, the question of whether the risk of balloon inflation is justified
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arises most commonly in patients with chronic ischemic cardiomyopathy who have nonstented target coronary arteries. This issue is less relevant to patients with acute
myocardial infarction, since in this setting the culprit vessel is usually stented during
revascularization and the risk of dissection or injury associated with balloon inflation is
therefore minimized. Accordingly, we decided to use a porcine model of old infarction
and scarred myocardium, which mimics the clinical setting of chronic ischemic
cardiomyopathy. Obviously, the effect of balloon inflation could not be studied in
rodents. We could have used less complex and expensive porcine models (e.g., pigs
without myocardial infarction or pigs with acute, rather than chronic, myocardial
infarction); however, these models would not be relevant to the large cohort of patients
with old stable myocardial infarcts (scars).
A variety of methods could have been used to assess cell retention at 24 h. The
advantage of our methodology, based on quantification of residual radioactivity, is that it
enabled us to assess the left ventricle as a whole. Alternative techniques such as PCRbased methods141, 170 have the advantage of high sensitivity and precision in small
samples, such as in murine hearts; however, they are not applicable to large tissue
samples because the large amount of native DNA in such samples would cause a dilution
in the targeted sequences of human genomic DNA of the residual hCPCs. This would
lead to an underestimation of cell numbers. Additionally, PCR-based methods, as well as
other methods such as fluorescence in situ hybridization of sex-mismatched donorrecipient pairs171 and nuclear affinity labeling for cell tracking160, enable quantification of
cell numbers only in small myocardial samples assumed to be representative of the whole
heart; these numbers must then be normalized to total myocardial weight to calculate
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global cardiac retention. Because cells may be distributed heterogeneously within the
heart, as observed in the present study (Figs. 4 and 5), these methodologies can
potentially lead to inaccurate quantification due to sampling bias. We obviated these
problems by measuring residual radioactivity in the entire heart.
In summary, using a clinically relevant porcine model of ischemic
cardiomyopathy, we have demonstrated that the stop-flow technique does not result in
superior hCPC retention 24 h after intracoronary infusion compared with non-occlusive
hCPC infusion. Therefore, the increased procedural risks associated with balloon
inflation do not appear to be warranted. These results have important practical
implications for the design of future clinical trials in which hCPCs (or other
stem/progenitor cells) are administered by the intracoronary route.
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CHAPTER III
SAFETY OF INTRACORONARY INFUSION OF 20 MILLION C-KIT POSITIVE
HUMAN CARDIAC PROGENITOR CELLS IN PIGS
Introduction
C-kitpos cardiac progenitor cells (CPCs) are one of a number of stem/progenitor
cells described in the mammalian heart and one of the two types ever used clinically for
cardiac regeneration.130, 148 We recently reported the results of the first in-human clinical
trial of autologous c-kitpos CPCs in patients with ischemic cardiomyopathy.148 In this
phase I trial, designed to evaluate the safety and feasibility of intracoronary
administration of c-kitpos CPCs, 1 million cells were injected in the infarct-related artery
using the stop-flow technique. The administration of c-kitpos CPCs was shown to be safe
and there were encouraging results related to efficacy, with a significant improvement in
left ventricular (LV) ejection fraction in the hCPC treated group. These encouraging
findings have sparked growing interest in utilizing c-kitpos CPCs in additional trials with
escalating doses >1 million cells, particularly in light of reports of dose-dependent
responses with stem cells.172 However, the safety of higher doses of c-kitpos CPCs has
never been evaluated in any clinical or preclinical model.
Intracoronary administration has been utilized with many cell types.
Mesenchymal stromal cells (MSCs) have been used in a large number of cardiac
regeneration trials. Although these cells are usually administered via transendocardial
injection, a number of clinical trials have used them intracoronarily.173-177 The cell dose
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in these studies ranged from 1 million to > 100 million cells.173-175, 177, 178 A number of
other studies are ongoing with intracoronary administration of MSCs (e.g., RELIEFNCT01652209). Nevertheless, there still exist important safety concerns with
intracoronary injection of MSCs.167, 179, 180 Grieve et al. demonstrated that although
intracoronary infusion of 25 million MSCs was safe, 75 million cells caused biochemical
and histological myocardial infarction in an ovine model.180 Similarly, Vulliet et al.
showed a dose-dependent rise in ST segments during intracoronary injection of MSCs in
all 7 dogs studied.167 The average size of MSCs and BMMNCs is ~21.0±3.3 μm and
8.6±1.8 μm, respectively.41, 181 At 7 to 10 μm, the typical capillary luminal diameter is
smaller than the average sized MSCs, the likely explanation for the findings in the
aforementioned studies.181, 182 In the CADUCEUS trial, 12.5 to 25 million cardiospherederived cells (CDCs) were injected intracoronarily with no significant safety concern.123
However, administration of 50 million allogeneic CDCs resulted in large infarctions in
pigs.181 Measuring 20.6±3.9 μm in diameter, CDCs are larger than the average capillary
diameter, thereby causing microvascular obstruction in that model. Finally, bone marrow
mononuclear cells (BMMNCs) have almost always been administered intracoronarily.
Close to 100 phase I and II clinical trials using large numbers of BMMNCs have
demonstrated that intracoronary administration is safe.183 For instance, within the three
phase II trials of BMMNCs led by the Cardiovascular Cell Therapy Research Network
(CCTRN), 100-150 million cells were administered intracoronarily with no
complications.184, 185
C-kitpos CPCs are similar in size to the unselected cell population from which they
are sorted, ranging from ~12 to 20 µm in diameter in suspension. Therefore, it is
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conceivable that they could bring about significant microvascular obstruction if
administered in high enough doses. Therefore, we set out to investigate the safety of 20
million intracoronarily delivered c-kitpos human CPCs, a dose ~40 times higher than that
used in our previous porcine study139, in a porcine model, as a preamble to future clinical
trials.
Methods
A detailed timeline of the experimental protocol is illustrated (Fig. 6).
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Fig. 6. Safety Study protocol and timeline.
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Human c-kit pos CPC isolation and expansion
Right atrial appendage specimens were obtained with IRB approval (IRB number
07.0062) from patients undergoing open-heart, on pump, coronary artery bypass surgery
at Jewish Hospital in Louisville, Kentucky. All patients were between the ages of 50 and
75 years of age, so as to approximate the ages of patients that were included in the
recently conducted SCIPIO phase I clinical trial.148 Right atrial appendages were
transported to the cell processing lab under sterile conditions on wet ice. The tissue was
washed several time with ice cold PBS to remove gross blood. Adipose tissue was then
resected manually from the external surface of the tissue with subsequent repeated
washing in cold PBS. The tissue was then manually minced to obtain fragments < 1mm3
(Fig. 7). The tissue fragments were then incubated on a shaking incubator at 37°C in
Worthington Collagenase type II/Hams F12 solution with multiple rounds enzymatic
digestion. Once complete, the solution of released cells was centrifuged with discarding
of the supernatant. The cells were washed in full growth media consisting of Ham’s F12
(Gibco), 10% FBS (Thermo Scientific Hyclone), 10ng/ml Recombinant Human bFGF
(PeproTech), 0.2mM L-Glutathion (Sigma), human Erythropoietin (Sigma), and 100U/ml
penicillin/streptomycin (Gibco). The supernatant was discarded and the cells were
resuspended in full growth media and plated in a 6-well plate for passage 0 initial
expansion. Media was changed at 24 h completely. Additional media changes were
performed every 3-4 days or if necessitated by visual examination of the culture. Cells
were expanded until 70% confluence at which time they were passaged to T75 Flasks for
additional subconfluent expansion prior to immunoselection for c-kit expression. Media
was added or changed partially every 3-4 days for the remainder of the culture process.
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Cells were passaged 1 time prior to immunomagnetic sorting for c-kit (CD117) using
Miltenyi immunomagnetic beads according to manufacturer’s recommendations.
Illustrations of the tissue processing and initial cell expansion are shown in Fig. 7.
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Fig. 7. Isolation and expansion of c-kitpos hCPCs. Right atrial appendages (RAA) were
harvested with subsequent mechanical and enzymatic digestion to obtain primary
outgrowth of total adherent cardiac cells. Primary cells were immunomagnetically sorted
for c-kit and the resultant cells expanded in vitro.
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c-kitpos hCPC immunomagnetic sorting (MACS)
Passage 1 cells at 70-75% confluence in T75 culture flasks were sorted for c-kit
with anti-CD117 Miltenyi microbeads and Miltenyi magnetic sorting apparatus (Fig. 7).
Cell sorting was performed through the direct technique. Cells were trypsined and
washed twice in ice cold MACS buffer made per manufacturer’s specifications. All
solutions were cooled on ice prior to beginning the sorting protocol. Cells were
immunomagnetically sorted according to manufacturer’s specifications using Miltenyi
MS columns and pre-separation filters with magnetic stand. Positively selected cells were
plated in 6-well plates at subconfluence for subsequent in vitro expansion of c-kitpos cells
(Fig. 7). Human c-kitpos CPCs were expanded exponentially over 3-4 additional passages
to ultimately obtain approximately 3 x 107 cells per patient. Multiple patients cells were
pooled to obtain a uniform cell product that was ultimately infused intracoronarily into
the treatment group of pigs (n = 9). Cells were assessed by flow cytometric analysis per
standard protocol for c-kit positivity at passage 3-4. Only populations of cells showing
greater than 70% c-kit positivity were used for the study.
Flow cytometric analysis and immunocytochemistry
Cells were trypsinized from dedicated flasks at passage 3-4 per standard protocol.
Cells were washed 1x in ice cold buffer with 1% bovine serum albumin (BSA)/phosphate
buffered saline (PBS) buffer followed by a second wash in cold PBS. Cells were then
fixed with 15 minutes at room temperature in freshly prepared or commercially
purchased 4% PFA buffered to pH 7. Fixed cells were washed twice in PBS. Cells were
stained for c-kit directly after fixation. Cells were blocked for 10 minutes at RT in 1%
BSA buffer and then stained for c-kit with c-terminal specific Santa Cruz C19 rabbit
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polyclonal IgG anti-human c-kit antibody for 1 h at room temperature in the dark.
Isotype rabbit polyclonal IgG in identical concentration was used in parallel as an isotype
control. Cells were then washed twice with 1% BSA buffer. Secondary antibody, FITC
or TRITC conjugated Invitrogen Donkey anti-rabbit IgG was then added for 1 h at room
temperature in the dark for flow cytometry or confocal microscopic imaging after cells
were spun onto glass slides. Confocal images were taken using Zeiss 510 inverted
confocal microscope and image processing performed relative to isotype control labeling
with integral instrument software only. Flow cytometric analysis was performed using
BD Accuri C6 flow cytometer. All analysis gates were set for false positivity of <1% in
respective isotype controls (Fig. 8). Accuri C6 software was used for final analysis of ckit positivity. Illustrations of flow plots and immunocytochemistry images (Fig. 8) as
well as data regarding c-kit positivity of all cell lines utilized for the study are shown
(Fig. 9). Only cell lines with greater than 70% c-kit positivity measured by flow
cytometric analysis were utilized for the study.

62

Fig. 8. Flow cytometric validation and immunocytochemistry of c-kitpos hCPCs.
Representative flow cytometric analyses of isotype control (left) and c-kit-labeled cell
flow plots (center) are shown. Suspension immunocytochemistry of c-kitpos hCPCs
showing positive anti-c-kit labeling is shown in the right panels, with DAPI labeled
nuclei in blue.
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Fig. 9. Cumulative c-kit positivity by flow cytometry and Trypan blue cell product
viability. The left panel shows c-kit positivity in seven cell lines utilized for the study,
which averaged 85.6%±1.9% (mean±SEM). The right panel shows viability of c-kitpos
hCPCs measured by cellular exclusion of Trypan blue staining prior to intracoronary
infusion. Trypan negative, viable cells averaged 97.8±0.4%. Data are mean±SEM.
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Cell product generation
Positively selected cells were expanded in vitro for 3-4 additional passages prior
to intracoronary infusion. In vitro expanded c-kitpos CPCs were trypsinized and washed
with sterile PBS and resuspended in 12mL of Plasmalyte-A solution. Final cell count and
viability by hemocytometer and Trypan blue were performed.

Cell number was

adjusted by volume to closely approximate 20 million cells in 12mL Plasmalyte-A
solution. The cells were placed on wet ice and transported to the cath lab for
intracoronary infusion.
Ethics Statement
This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Louisville (IACUC number: 12114).
Animal procedures
Female Yorkshire pigs (weight 32.4 ± 0.7 kg, age: 13.4 ± 0.3 weeks) were used
for this study. All animal procedures were approved by the University of Louisville
IACUC (IACUC number 12114) prior to initiation of the study. Pigs were fasted for at
least 12 h prior to sedation. On the day of cell delivery, pigs received a prophylactic dose
of antibiotics (Ceftiofur 3 mg/kg, IM) and a preemptive dose of analgesics
(buprenorphine 0.025 mg/kg, IM). Pigs were sedated using a cocktail of ketamine (20
mg/kg, i.m.) and xylazine (2 mg/kg, i.m.). An intravenous catheter was placed in a
marginal ear vein for the administration of fluids and drugs. Animal received diazepam (1
mg/kg IV) to facilitate intubation. Following adequate sedation, pigs were intubated and
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mechanically ventilated. General anesthesia was maintained with isoflurane (1.5% 2.0% 50/50 oxygen/nitrogen). Pigs received aspirin (2300 mg, IV) and heparin (300
U/kg, IV) before the catheterization procedure.
A cut-down on the right neck was performed and the right jugular was used for
placement of a 7-10 F chronic cath polyurethane catheter (Access Technologies or
Bard/Hickman). This catheter was implanted, secured, tunneled to the back of the neck
and kept in place for the duration of the 1 month follow-up for serial blood collections;
using this catheter, blood samples were obtained for serial measurement of cardiac
markers at baseline (before catheterization procedure) and at 6, 12, 24 h, and 1 week, and
1 month after cell delivery (Fig. 6). The catheter dead-space was measured and filled with
heparin (1000 units/mL) after each withdrawal to maintain patency. Care was taken to fill
the dead-space only with no spillover into the systemic circulation after each blood
collection.
At the end of the 1 month follow up, pigs were anesthetized with 22 mg/kg
ketamine and 2 mg/kg xylazine IM. Pig was transported to the cath lab for final
hemodynamic measurement. Animals received diazepam 1 mg/kg IV to facilitate
intubation. Animals were then again intubated and ventilated. General anesthesia was
maintained with isoflurane (1.5% - 2.0% 50/50 oxygen/nitrogen). Hemodynamic
variables were monitored and recorded. After the final hemodynamic recording was
taken, the animal was deeply anesthetized with 5% isoflurane. A bolus of 3-6 ml/kg of 3
mmol/ml potassium chloride solution was injected intravenously until the heart was
completely arrested. Asystole was confirmed by cessation of cardiac electric activity
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from ECG monitoring. The chest was opened via a left thoracotomy, the aorta was
transected, and the pig exsanguinated. The heart was then harvested.
Cell delivery / catheterization procedure
Through a right femoral artery cut-down, a 7F fast-cath sheath was introduced. A
6 F Hockey-stick catheter (Cordis) was fluoroscopically guided to the left main coronary
artery. The left main coronary ostium was engaged by the catheter and an angioplastytype balloon catheter (Maverick 2.0 x 9 mm) and guide wire (BMW, Boston Scientific)
assembly was guided into the LAD; the wire was advanced into the mid LAD and the
catheter telescoped over the wire and positioned just proximal to the 1st diagonal branch.
The CPC solution (20 million cells in 12 ml of sterile Plasma-Lyte A solution or vehicle,
divided by 4 injections, 3 ml each, interspersed with 4’30” between each injection) or
vehicle (12 ml of sterile Plasma-Lyte A solution) was injected manually at a constant rate
through the central port of the angioplasty balloon catheter over the 3 min. After the
procedure, the Hockey-stick catheter, and the femoral sheath were removed and the groin
access site was closed in 3 layers using 3-0 PDS suture. A transdermal fentanyl patch (2.5
µg/kg/h) was placed at the end of the procedure for postoperative analgesics. The pigs
were weaned from anesthesia, extubated, and moved to a post-operative area for
postoperative monitoring. Ceftiofur (3 mg/kg, s.c.) was be repeated on day 1 and 2 postprocedure.
Immunosuppressive Therapy
Pigs received 15 mg/kg/day of Cyclosporine A (CsA) starting 2 days before cell
injection and continuing until the end of follow-up. CsA (powder from Novartis) was
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mixed with a tablespoon of grape flavored Kool-Aid powder and ~60 ml of drinking
water to make a suspension beverage to feed the animal orally.
Echocardiography
Echocardiograms were obtained at baseline (before CSC delivery), 24 h, 1 week,
and 1 month after CSC delivery (Fig. 6) using a HP SONOS 7500 ultrasound system
(Philips Medical Systems) equipped with a HP 21350A (S8) 3.0-8.0 MHz sector array
ultrasound transducer. Before the echocardiographic study, pigs were anesthetized
(isoflurane) and placed in the left lateral decubitus position. Temperature was monitored
with a rectal temperature probe and kept between 37.0°C and 37.5°C with a heating pad.
The parasternal short-axis view was used to obtain 2D and M-mode images19. Systolic
and diastolic anatomic parameters were obtained from M-mode tracings at the midpapillary level. Digital images were analyzed off-line by a single blinded observer using
ComPACS Review Station (version 10.5) image analysis software (Medimatic, Las
Cruces, NM 88004, USA ) according to the American Society of Echocardiography
standards.158
Cardiac biomarkers assays: Troponin I and CK-MB
Plasma cTnI levels were measured with a pig cTnI ELISA kit according to the
manufacturer’s instruction (Life Diagnostics, West Chester, PA) at baseline as well as 6,
12, and 24 hrs, and one week and one month post infusion (Fig. 6). Fresh blood was
collected with the heparinized tube and then centrifuged to separate plasma from the
blood sample. Each assay was performed in duplicate and in a blinded fashion. The
original cTnI data (i.e., the optical density absorbance values acquired from Beckman
Coulter DU730 Spectrophotometer) were calibrated and converted with cTnI standard
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curve. The final cTnI results were expressed as nanogram per milliliter plasma (ng/ml).
All measurements were performed in duplicate.
Plasma CK-MB concentration was measured via an ELISA kit (MyBioSource) at
baseline as well as 6, 12, and 24 hrs, and one week and one month post infusion (Fig. 6).
Briefly, the 96-well plate was pre-coated with an antibody specific to pig CK-MB. The
plasma samples were loaded onto the wells and bound by the pre-coated specific
antibody. Then a biotinylated detection antibody specific for pig CK-MB and AvidinHorseradish Peroxidase (HRP) conjugate were added to the wells. After incubation, free
components were washed away. The substrate solution was added to each well. Only the
wells contained CK-MB protein, biotinylated detection antibody and Avidin-HRP
conjugate presented blue in color. This enzyme-substrate reaction was terminated by the
addition of a sulphuric acid solution, therefore the color turned to yellow. The optical
density (OD) was measured spectrophotometrically at a wavelength of 450 nm. The
original CK-MB data (i.e., OD values) in the pig plasma samples were calculated and
converted with pig CK-MB standard curve. Duplicate assays were performed for each
sample and CK-MB concentration was expressed as nanogram per milliliter of plasma
(ng/ml). All CK-MB assays and calculation were conducted in a blinded fashion relative
to hCSC treated vs control group. All measurements were performed in duplicate.
Assessment of renal and hepatic function
Functions were assessed by measurement of respective biomarkers. Peripheral
blood was drawn and complete metabolic panels (CMPs) were obtained in hCSC-treated
and control groups at baseline and 6, 12, and 24 h, 1 week, and 1 month after
intracoronary infusion (Fig. 6). All CMPs were analyzed by the veterinary lab company
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Antech Diagnostics (Louisville, Ky) in a blinded fashion. Resultant biomarker values
were compared with known porcine reference ranges provided by Antech Diagnostic as
well as with absolute initial baseline values. Changes in blood urea nitrogen (BUN) and
creatinine (Cr) were used to assess renal function. Change in AST, ALT, alkaline
phosphatase (Alk Phos), and total creatine phosphokinase (CPK) were used to assess
hepatic function.
DNA isolation from paraffin embedded sections and PCR
Genomic DNA was isolated from representative paraffin embedded left
ventricular tissue sections using QIAamp DNA FFPE Tissue Kit (Qiagen) according to
the manufacturer’s instructions. Samples were analyzed for the presence of human (HLADMA) and pig (Pig Gapdh) genomic DNA using the following primer sets:
HLA-DMA fwd, 5’-TACAAACCTCAGCTACCTTCGTGGC-3’
HLA-DMA rev, 5’-AACCCAGCTGACTCTGGGTGG-3’
Pig Gapdh fwd, 5’-CCCCCTCAGATTTGGCCGCA-3’
Pig Gapdh rev, 5’-CACGGGGGCCACTCACCAT-3’
For PCR reaction, 100 ng of each DNA sample was amplified in a 20 µl reaction
for 40 cycles (denaturation at 95 ºC; annealing at 61 ºC; and extension at 72 ºC) using
Taq 2X Master Mix (New England Biolabs). Accordingly, the limiting threshold or
sensitivity of detection of human CSCs approximated 1 hCSC per 15,000 porcine cells.
Statistical Analyses
One or two-way repeated measures ANOVA statistical analysis was employed for
all comparisons of echocardiographic parameters as well as cardiac, hepatic, and renal
biomarkers between groups across multiple time points where applicable. All data are
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represented as means ± SEM. Datasets are illustrated in the supplemental supporting
information.
Results
Intracoronary infusion of 20 million c-kitpos CPCs does not impair LV function or
structure
Echocardiographic measurements were performed at serial time points after
intracoronary infusion of 20 million human c-kitpos CPCs (n=9) or vehicle (n=5) (Fig.
10). Baseline parameters were not significantly different between the two groups. No
significant change in left ventricular (LV) function or dimensions occurred as a result of
the infusion. For example, LV ejection fraction (EF) did not differ between hCPCtreated and vehicle controls at any time point (baseline: 55.8±1.8% vs 60.3±2.9%,
respectively; 24 h: 56.9±1.6% vs 59.2±1.6%; 1 week: 58.2±1.7% vs 58.0±1.6%; 1 month:
58.0±2.0 vs 59.0±1.1) (Fig. 10A&E); changes within groups compared with baseline
were also not significantly different (P>0.05). Mean anterior wall thickening fraction was
examined in the treatment group and was not observed to be significantly different before
(58.4±4.9%) vs 24 h after CSC infusion (57.5±6.2%), P>0.05 (Fig. 10D). Similarly, there
was no significant difference in LV end-diastolic diameter, fractional shortening, enddiastolic volume, end-systolic volume, end-systolic diameter and anterior and posterior
wall thickness in both systole and diastole. These data indicate that the intracoronary
infusion of hCPCs had no deleterious effect on LV function and dimensions.
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Fig. 10. Intracoronary infusion of 20 million human c-kitpos CPCs does not impair
left ventricular (LV) function or morphology. The line graphs in the top panel show
individual values of each pig’s progress over time (baseline, 6, 12, 24 h, 1 week, and 1
month). Individual plots are in yellow, and group means are illustrated by the red line
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plots. A. ejection fraction (EF). B. LV end-diastolic diameter (EDD). C. LV end-diastolic
volume (EDV), D. LV anterior wall fractional thickening. The bottom panel shows group
mean±SEM at each time point for respective LV functional and morphologic indices.
Green and red bars indicate hCSC-treated and vehicle groups respectively. E. ejection
fraction, F. fractional shortening, G. LV end-systolic area, H. LV end-diastolic area, I.
LV end-systolic volume, J. LV end-diastolic volume, K. LV anterior wall thickness in
systole, L. LV anterior wall thickness in diastole, M. LV end-systolic diameter, N. LV
end-diastolic diameter, O. LV posterior wall thickness in systole, P. LV posterior wall
thickness in diastole. Data are mean±SEM. There were no significant differences
between groups with respect to any parameter at respective time points (P > 0.05).
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Intracoronary infusion of 20 million c-kitpos CPCs does not cause ischemic myocardial
injury
Myocardial injury resulting from possible micro-embolization and ischemia was
assessed by serial measurements of plasma cTnI (Fig. 11) and CK-MB levels (Fig. 12).
In both c-kitpos CPCs-treated and vehicle controls, cTnI levels rose slightly after
catheterization and intracoronary infusion, peaking at 6 h post catheterization in both
groups (hCPC treated, 1.3±0.68 vs. 0.08±0.08 ng/ml at baseline; controls, 1.4±0.58 vs,
0.07±0.08 ng/ml at baseline). In both groups, cTnI returned to baseline by 12 h and
remained at baseline levels at 24 h, 1 week, and 1 month after infusion. At no time-point
during the study was there a significant difference in plasma cTnI levels between the two
groups. In addition, total cumulative myocardial cTnI release did not differ significantly
between the hCSC-treated and vehicle-treated groups. Plasma levels of CK-MB
exhibited a very slight but clinically irrelevant increase from baseline in both groups,
(0.068±0.01 vs 0.039±0.01 ng/ml at baseline in the treated group; 0.058±0.013 vs
0.039±0.01 ng/ml at baseline in the control group) peaking at 12 h in the treatment group
and 24 h in the control group. Importantly, neither peak mean nor cumulative enzyme
levels differed significantly between vehicle-treated and hCPC-treated groups, indicating
that hCPC delivery was not associated with myocardial injury(P>0.05).
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Fig. 11. Intracoronary infusion of 20 million human c-kitpos CPCs does not cause
myocardial damage as assessed by cardiac troponin I (cTnI) release. A. Individual
plots of serum cTnI levels (ng/ml) are shown at serial time points (baseline, 6, 12, 24 h, 1
week, and 1 month). Green and red plots indicate hCPC-treated and vehicle control pigs,
respectively. B. Group means at each time point are shown. The green and red plots
indicate hCPC-treated and vehicle control groups, respectively. The inset in panel B
shows cumulative cTnI levels. Data are mean±SEM. There were no significant
differences in plasma cTnI levels over the 1 month follow up between groups (P > 0.05 at
each time point).
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Fig. 12. Intracoronary infusion of 20 million human c-kitpos CPCs does not cause
myocardial damage as assessed by cardiac CK-MB release. A. Individual serum CKMB levels (ng/ml) over serial time points (baseline, 6, 12, 24 h, 1 week, and 1 month).
Green and red plots identify hCSC-treated and vehicle control pigs, respectively. B.
Group means at each time point are shown. The green and red plots identify hCPCtreated and vehicle control groups, respectively. The inset in panel B shows cumulative
CK-MB levels. Data are mean±SEM. There were no significant differences in plasma
CK-MB levels over the 1 month follow up between groups (P > 0.05 at each time point).
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Intracoronary infusion of 20 million c c-kitpos CPCs does not impair renal function
Serum creatinine and BUN levels rose approximated 25% over baseline in the
first 12-24 h in both the hCPC-treated and the vehicle groups (Fig. 13). In the treated
group, creatinine increased from 1.32 mg/dL to 1.68 mg/dL at 6 h after catheterization; a
similar pattern was observed in the control group, in which creatinine increased from
1.54 mg/dL at baseline to 2.04 mg/dL at 6 h after catheterization. Serum creatinine levels
returned to baseline values in both groups by 24 h, and no changes were observed at 1
week and 1 month (Fig. 13A). Serum BUN levels showed a similar pattern of transient
increase at 6 h followed by a return to baseline levels (Fig. 13B). There was no
significant difference at any time point between hCPC-treated and control pigs with
respect to either creatinine or BUN serum levels, indicating that the slight increases
observed at 6 h were not due to the infusion of hCPCs.
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Fig. 13. Intracoronary infusion of 20 million human c c-kitpos CPCs does not impair
renal function. Renal function was assessed by serum creatinine and blood urea nitrogen
(BUN) values over serial time-points (baseline, 6, 12, 24 h, 1 week, and 1 month). A.
Bar graph of serum creatinine levels in hCPC-treated and vehicle control group . B. Bar
graph of serum BUN levels in hCPC-treated and vehicle control group. Blue and purple
bars identify hCPC-treated and vehicle control groups, respectively. Upper limits of
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normal (ULN) and lower limits of normal (LLN) in each graph are depicted by dashed
lines respectively. Data are mean±SEM. There were no significant differences in serum
creatinine or BUN levels over the 1 month follow up between groups (P > 0.05 at each
time point).
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Intracoronary infusion of 20 million c-kitpos CPCs does not impair hepatic function
Serum AST, ALT, alkaline phosphatase, and total CPK levels were significantly
higher after catheterization (P< 0.05 vs. baseline) in both hCPC-treated and control
groups (Fig. 14). Specifically, AST increased to levels four times (200-400 IU/L) the
upper limit of normal (45-83 IU/L), peaking 24 h after catheterization (Fig. 14A). ALT
also increased but did not surpass the upper limits of normal (52-81 IU/L) in either
treatment (61.8±23.6 IU/L) or control (67.6±23.0 IU/L) groups (Fig. 14D). There was no
significant difference between hCPC-treated and control pigs in either AST or ALT,
indicating that the rise in these markers was not due to the infused cell product. All
values were within normal limits 1 week and 1 month after catheterization (P>0.05 vs.
baseline).
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Fig. 14. Intracoronary infusion of 20 million human c-kitpos CPCs does not impair
liver function. Liver function was assessed by serum AST, ALT, alkaline phosphatase,
and total CK levels at serial time points (baseline, 6, 12, 24 h, 1 week, and 1 month). A.
Serum aspartate aminotransferase (AST), B. Serum creatine phosphokinase (CPK), C.
Serum alkaline phosphatase (Alk. Phos.), D. Serum alanine aminotransferase (ALT).
Upper limits of normal) and lower limits of normal (LLN) in each graph are depicted by
dashed lines respectively. Data are mean±SEM. There were no significant differences in
serum AST, ALT, alkaline phosphatase, or total CK levels over the 1 month follow up
between groups (P > 0.05 at each time point).
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Intracardiac retention of c-kitpos CPCs in pigs 30 days post intracoronary infusion
To assess the number of hCPCs retained in the porcine heart 30 days after
intracoronary infusion, genomic DNA was isolated from anterior portions of the left
ventricle and analyzed by PCR for the presence of human genomic DNA (HLA-DMA)
(Fig. 15). No human DNA could be detected in any control (lanes 1-5) or human CSCtreated (lanes 6-14) LV samples, indicating the retention of human CPCs was minimal
and/or below the detection limit of our assay (1 hCPC per 15,000 porcine cells). Samples
were also analyzed for the presence of pig genomic DNA (Gapdh) as a control for DNA
quality. Porcine DNA was detected in all samples.
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Fig. 15. Detection of human CPCs in control versus hCPC-treated pig hearts.
Genomic DNA isolated from representative LV sections from control (lanes 1-5) and
human CSC-treated pigs (lanes 6-14) were analyzed by PCR for the presence of human
genomic DNA (HLA-DMA). Samples were also analyzed for the presence of pig
genomic DNA (Gapdh) as a control for DNA quality. Genomic DNA isolated from
human heart sections was used as both positive and negative control. None of the
samples, including CSC-treated ones, show detectable levels of human DNA.
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Discussion
The present study was conducted to assess the safety of intracoronary infusion of
20 million c-kitpos CPCs. We have previously found in a porcine model of ischemic
cardiomyopathy that intracoronary delivery of 500,000 autologous c-kitpos CPCs, which
is roughly equivalent to 1 million CSCs in humans, does not result in apparent cardiac
injury. The SCIPIO trial showed that intracoronary infusion of 1 million autologous ckitpos CPCs in humans is safe and may produce beneficial effects on cardiac function,
myocardial scar size, and functional capacity. However, the dose employed in SCIPIO
was relatively low (compared with other trials that have infused, for example, 25
million123 or even >200 million186 cells). Evidence suggests that higher doses of cells
may be more efficacious.161 It is currently unknown whether doses of hCPCs greater than
1 million can be safely administered intracoronarily. Therefore, we conducted the
present study with a dose of cells 40 times higher than that used in our previous study139
as a preamble to future clinical trials. To our knowledge, our infused dose of 20 million
human c-kitpos CPCs delivered intracoronarily is the highest dose ever attempted in any
clinical or preclinical model using hCSCs.
The results of the present study indicate that intracoronary infusion of 20 million
c-kitpos CPCs is safe. This higher dose did not result in any evidence of myocardial
injury, impairment in regional or global cardiac function, deterioration of renal or hepatic
function, or other adverse effects, either in the immediate post-infusion period or during
the subsequent month, compared with vehicle (Figs. 10-14). Very small, transient
increases in plasma troponin I were observed after catheterization in both groups (Fig.
11) but were not associated with any measurable impairment in LV function (Fig. 10).

84

These low-level, transient increases in plasma troponin are not dissimilar from those seen
in prior studies139; given their low magnitude and brief duration, they are likely
insignificant. Importantly, since they were observed in both groups, they cannot be
attributed to the hCPC product. We suspect that these early transient increases in plasma
troponin I in both hCPC- and vehicle-treated animals may have been, at least in part, a
result of the observed impairment in renal function caused by exposure to cyclosporine
and a large intravenous contrast load. Indeed, the time-course of renal dysfunction
coincided with the transient rise and resolution of plasma troponin over the first 12-24 h
following catheterization. Renal dysfunction, decreased creatinine clearance, and uremia
have been implicated in increased plasma levels of troponin in patients without acute
myocardial injury.187 In clinical studies in which elevations of plasma troponin were
related to renal dysfunction, acute myocardial injury was excluded by observing a lack of
parallel elevations in plasma CK-MB.187 This pattern of low-level troponin increase with
minimal or no concurrent increase in CK-MB during a period of renal impairment
mirrors the pattern of cardiac biomarkers observed in the present study. It is possible that
other factors associated with cardiac catheterization also contributed to the slight rise in
plasma troponin. In any case, the fact that vehicle-treated pigs exhibited similar
elevations despite receiving no hCPCs indicates the elevations in treated pigs were not
caused by hCPCs but, rather, by mechanisms that affected both groups.
Our findings are consistent with previous studies documenting the safety of
intracoronary infusion (without stop flow) of similar numbers of other cell types,
including bone marrow derived MSCs.188, 189 Specifically, Suzuki et al188 demonstrated
the safety and efficacy of 45 million MSCs infused intracoronarily without stop-flow; the
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authors observed myocyte regeneration and improved cardiac function without any
evidence of myocardial necrosis related to the infusion.188 The same group observed a
similar safety and efficacy profile following intracoronary infusion (without stop flow) of
30 million cardiosphere-derived cells divided among each of three coronary vessels.189
Again, no significant TnI elevation was observed.
As mentioned above, after the catheterization procedure renal function was
transiently impaired in both treated and control groups (Fig. 13), indicating that the
decline in creatinine clearance was not due to systemic distribution of hCPCs and renal
microembolization. The mild degree and brief duration of renal impairment, along with
the complete return of creatinine and BUN to baseline levels within 24 h after
catheterization in both groups, indicates that the etiology was most likely related to the
contrast administered intravenously during coronary angiography. Contrast-induced
nephropathy (CIN) is commonly observed in clinical settings, with temporary decreases
in creatinine clearance that usually return to normal values within 24-48 h.190
Concomitant exposure of pigs to cyclosporine likely predisposed to the occurrence of
CIN and decreased creatinine clearance, since both cyclosporine and intravenous contrast
exposure produce vasoconstriction of renal afferent arterioles190, 191, which in turn
decreases the glomerular filtration rate.
A slight, transient impairment in liver function was also observed (Fig. 14). But
again, this phenomenon was seen in both hCPC-treated and vehicle-treated pigs, and the
duration and magnitude were not significantly different between groups, indicating that
the elevated levels of AST, ALT, and alkaline phosphatase were not caused by
intracoronarily delivered hCPCs. ALT, being more specific for liver injury than either
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AST or alkaline phosphatase192, did not increase above the upper limits of normal (51-82
IU/L) (Fig. 14D). In fact, a hepatic source of these elevated biomarkers is highly
unlikely. While leak of aminotransferases into the systemic circulation can indicate liver
injury, the liver is not the only source of these biomarkers and caution should be observed
in clinical interpretation.192 Increases in these biomarkers are also seen with skeletal
muscle injury.192, 193 In our porcine model, a cut-down procedure was used to provide
unrestricted access to the femoral artery for arterial sheath and catheter placement. The
resultant soft tissue and skeletal muscle injury provides a non-hepatic source of elevated
transaminases. This is confirmed by the concurrent increase in muscle specific creatine
phosphokinase (CPK) (Fig. 14B), which mirrored the magnitude and duration of the rise
in transaminase levels (Fig. 14A). All of these markers returned to baseline levels
concurrently.
Despite the high dose of 20 million cells, myocardial retention of c-kitpos CPCs 30
days after intracoronary infusion was observed to be minimal and below the threshold of
detection as measured by PCR targeting human genomic DNA. In our experience, this
finding is neither surprising nor unexpected. Previous studies141, 143, 170 have also found
minimal retention 30-35 days after c-kitpos CPCs administration in rodent models.
Additionally, in the current study, human c-kitpos CPCs were infused as a xenograft, and
only cyclosporine was utilized to prevent acute rejection. The animal’s immune reaction
to these human cells is not likely to be completely suppressed by cyclosporine alone over
a 35-day time period, and thus is likely to have contributed to the attrition of the human
cells via immune clearance. In a recent study performed to quantify hCPC engraftment
and retention in pigs after intracoronary infusion of 10 million Indium111-radiolabeled c-
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kitpos CPCs, we found that just 4-5% of the infused cells remained in the entire heart at 24
h.194 Additionally, in this study we compared intracoronary infusion both with and
without utilization of the stop-flow technique, and found no significant difference
between the two methodologies with respect to hCPC retention at 24 h. This would
suggest that the negligible level of hCSC cardiac retention observed in the present study
was not due to the fact that we did not use the stop flow technique. However, it should
be pointed out that in the current study we infused cells into normal, noninfarcted hearts
(this was done in order to maximize the sensitivity of our model in detecting any
myocardial damage caused by the high dose of 20 million hCPCs). This may have
accelerated the disappearance of hCPCs from the myocardium by negatively impacting
the homing and/or adhesion of the hCPCs to damaged tissue that occurs in the setting of
ischemic cardiomyopathy.195, 196
In conclusion, intracoronary infusion of 20 million human c-kitpos CPCs in pigs
(equivalent to ~40 million hCPCs in humans) does not cause acute myocardial injury,
impaired regional or global myocardial function, adverse changes in LV dimensions, or
liver and renal injury. These results have immediate translational value and lay the
groundwork for using doses of CPCs >1 million in future clinical trials. Further studies
are needed to determine whether doses of c-kitpos CPCs >1 million result in greater
efficacy in patients with ischemic cardiomyopathy.
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CHAPTER IV
A NOVEL POPULATIONOF HUMAN CARDIAC PROGENITOR CELLS
EXPRESSING STAGE-SPECIFIC EMBRYONIC ANTIGEN-3: PHENOTYPE AND
THERAPUTIC UTILITY IN A MURINE MODEL OF ISCHEMIC
CARDIOMYOPATHY

Introduction
The discovery that the human heart intrinsically possesses cells with multipotent
and transdifferentiation capacities has overturned the long held dogma that the postnatal
heart is a static organ. Numerous cell types have been isolated from the adult human
myocardium by various methodologies and studied relative to their ability to minimize or
reverse ischemic myocardial injury either by stimulation of mechanisms that initiate
reverse remodeling or by induction of myocardial neovascularization and/or formation of
new viable myocardium. The most widely studied include c-kitpos cardiac progenitor
cells (CPCs) and cardiosphere derived cells (CDCs), which have shown to impart
salubrious clinical effects in patients with ischemic cardiomyopathy.123, 148 Epicardial
derived progenitor cells (EPDCs) have also been widely characterized, but evaluation of
their therapeutic potential has been limited to preclinical models. While the embryonic
origin of adult EPDCs has been widely studied, originating from proepicardial
progenitors during fetal cardiomyogenesis and persisting into adulthood,84, 197 the
embryonic origins of c-kitpos CPCs and cells that give rise to CDCs under in vitro
conditions remain unclear.10 Evidence suggesting the possibility of an upstream c-kit
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negative progenitor that may give rise to c-kitpos CPCs within the heart may indirectly be
proposed based on the discovery by Klarmann et al that c-kit positive hematopoietic stem
cells arise from a c-kit negative, hematopoietic lineage (lin) negative precursor within the
bone marrow.131 Beltrami et al allude to this hypothetical hierarchy within the heart and
existence of such a progenitor population that may give rise to c-kitpos CPCs.130 Similarly,
the mesenchymal phenotype and reported multipotentiality of cells generated by the
cardiosphere method would indicate that the human heart harbors a yet unidentified
multipotent mesenchymal stem cell population that may give rise to mature myocardial
lineages.198 Gaps in knowledge remain regarding intrinsic cardiac progenitor pools
responsible for myocardial homeostasis and repair because discrete markers that
distinguish such upstream, undifferentiated progenitor populations remain to be
identified. Based on this, we began to explore markers not previously defined within the
human heart that have been associated with stemness capacity in other stem cell
populations, and we sought to determine whether such markers could aid in the
identification of cardiac cell populations that might be utilized for therapeutic purposes.
Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs),
as well as some tissue specific mesenchymal stem cells (MSCs) from cord blood199, adult
bone marrow200-202, adipose tissue201, 202, and dermis202-204 have been found to express the
glycosphingolipids stage-specific embryonic antigens (SSEA)-3 and SSEA-4, antigens
first characterized in undifferentiated carcinomas.205, 206 SSEA-3 and SSEA-4 expression
is observed to be lost with lineage commitment and differentiation as the core structures
of glycosphingolipid expression in stem cells switches from globo- and lacto- to ganglioseries.207 SSEA-3 has shown to be more rapidly down regulated than SSEA-4 indicating
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that the presence of SSEA-3 is associated with a more primitive state than is SSEA-4
positivity alone.207 The existence of myocardial cells expressing SSEA-4 has been
previously described within neonatal and some adult cardiac mesenchymal cells202, 208
although the presence of SSEA-3 expression remained undefined. Equivalents of human
SSEA-3 have been previously observed within adult rat myocardium.209 In the present
study, we sought to ascertain whether the adult human heart harbored a yet unidentified
population of cells with a stemness associated phenotype expressing SSEA-3, and
whether SSEA-3 expressing myocardial cells may be utilized in therapeutic applications
for myocardial repair after ischemic injury. For the first time, we report the discovery,
isolation, characterization, and therapeutic potential of a novel population of cardiac
progenitor cells expressing SSEA-3.
Methods
Acquisition of Human Right Atrial Appendage Specimens
Right atrial appendage specimens were obtained with IRB approval from patients
undergoing open heart, on-pump, coronary artery bypass surgery from 2011 to 2015 at
Jewish Hospital and Kosair Children’s Hospital (IRB number 07.0062) in Louisville, KY.
All research was performed in accordance with HHS Regulations (45 CFR Part 46) Protection of Human Subjects and respective exemptions.
Tissue Processing
Right atrial appendages (~20-400 mg) were rinsed with ice-cold 1X PBS,
weighed, and manually minced (fragments < 1 mm3) with sterile surgical scissors. Tissue
fragments were subsequently washed twice in ice-cold Ham’s F12 base media and
enzymatically digested with Worthington Collagenase type II/Hams F12 solution
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(1500U/mL; 10 mL per 100 mg of tissue) for 90 min at 37°C with gentle agitation.
Resultant cells were harvested via centrifugation (400xg for 5 min), and washed in
SSEA-3 cell growth media consisting of a combination of mTESR1 media (STEMCELL
Technologies) containing 20% FBS (Seradigm) and basal growth media [Ham’s F12
(Gibco) supplemented with 10% FBS (Seradigm), 10 ng/ml Recombinant Human bFGF
(PeproTech), 0.2 mM L-Glutathione (Sigma), 0.005 U/mL human erythropoietin
(Sigma), and 100 U/ml penicillin/streptomycin (Gibco)]. Ultimately, the mTESR1 and
basal media were combined in a 60/40 ratio, respectively, to generate the initial passage
(P0) SSEA-3 cell growth media. Cells were resuspended in SSEA-3 cell growth media
and plated in 6-well plates for primary expansion (passage 0). Media was removed at 24
h and placed in an empty adjacent well to provide further time for adhesion of cells
remaining in suspension at 24 h. These were termed secondary cultures. 2 mL of fresh
SSEA-3 cell growth media was added to the primary wells. 24 h later, media was
changed in secondary cultures. Additional media changes were performed every 3 days
in both primary and secondary cultures. Cells were expanded until 70-80% confluence at
which time they were passaged to T75 Flasks (passage 1) for additional expansion prior
to immunoselection for SSEA-3 expression. Primary and secondary unsorted cultures
were combined at the time of passaging to T75 flasks. Illustrations of the tissue
processing and initial cell expansion are similar to what was demonstrated in Figure 7.
FACS sorting of SSEA-3pos linneg cells
Passage 1 cardiac cells were trypsinized and sorted for SSEA-3 expression.
Briefly, cells at 70-80% confluence were trypsinized, washed with ice-cold MACS
buffer, and labeled with Ebioscience PE- or Alexa-488-conjugated Rat IgM Anti-
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Human/Mouse SSEA-3 for 30 min per the manufacturer’s instructions. Cells were sorted
using a Beckman Coulter MoFlo cell sorter. Gates were set to isolate the highest 1-2%
SSEA-3 positive events as well as the least positive (SSEA-3 negative) events.
Immunomagnetic sorting for SSEA-3pos linneg cells
Passage 1 cells at 70-80% confluence were immunomagnetically sorted for
SSEA-3 according to the manufacturer’s specifications using Miltenyi MS columns in
conjunction with pre-separation filters. Briefly, cells were trypsinized, washed twice in
ice-cold MACS buffer (1% BSA), suspended in 300 µl 1% BSA MACS buffer, and
incubated with 15 µl of primary antibody (Ebioscience PE-conjugated rat IgM antihuman/mouse SSEA-3) for 20 min. Subsequently, cells were washed with 1% BSA
MACS buffer, suspended in 80 µl 1% BSA MACS buffer, and incubated with 20 µl
Miltenyi Mouse IgG anti-PE microbead antibody for 20 min. Cells were then washed in
10 mL sterile 1% BSA MACS buffer, suspended in 500 ul 1% BSA MACS buffer, and
loaded onto a primed magnetic column with a 30 µm pre-separation filter. Elution
procedures were performed according to the manufacturer’s MS column protocol.
Positively selected cells were plated in T75 flasks at subconfluence for subsequent in
vitro expansion of human SSEA-3pos linneg cells. Human SSEA-3pos linneg cells were used
immediately or expanded exponentially over 2 additional passages to obtain
approximately 3-20 x 106 cells for use in both in vitro and in vivo studies. Cells were
assessed by flow cytometric analysis for SSEA-3 positivity at passage 2 following
immunomagnetic sorting.
Flow cytometric analysis
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Cells were trypsinized from dedicated flasks at passage 2 with TrypLE (Life
Technologies) and then washed 2 times with 1% BSA MACS buffer (Miltenyi). Cells
were incubated with Ebioscience rat IgM anti-human SSEA-3 Alexa Fluor 488conjugated antibody for 45 min. Isotype control Ebioscience Alexa Fluor 488-conjugated
Rat IgM was used in parallel to establish gating for flow cytometric analyses. All
antibodies were used at manufacturer suggested concentrations. Flow cytometric
analysis was performed using a BD Accuri C6 flow cytometer or BD LSR flow
cytometer. Gates were set for false positivity of <1% in respective isotype controls.
Figures and illustrations of resultant flow plots were obtained by generating jpeg images
directly from the instrument without the use of any additional software. A comprehensive
list of antibodies utilized for flow cytometric analyses is provided in Table 1.
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Table 1.
Flow Cytometry
Marker

Manufacturer

Species (anti-human)

SSEA-3

Ebioscience

Rat IgM

SSEA-4

Ebioscience

Mouse IgG3

KDR
CD31
CD31
c-kit
c-kit
CD34
CD34
CD45
CD45
CD105
CD73
CD90
CD29
CD44
CD166
HLA-I
HLA-II
TRA-1-60
TRA-1-81
CD15

R&D systems
BD
Ebioscience
Ebioscience
Sant Cruz
BD
Ebioscience
BD
Ebioscience
Ebioscience
Ebioscience
Ebioscience
Ebioscience
Ebioscience
Ebioscience
BD
BD
Ebioscience
Ebioscience
BD

Mouse IgG1
Mouse IgG1
Mouse IgG1
Mouse IgG1
Rabbit IgG
Mouse IgG1
Mouse IgG1
Mouse IgG1
Mouse IgG1
Mouse IgG1
Mouse IgG1
Mouse IgG1
Mouse IgG1
Rat IgG2b
Mouse IgG1
Mouse IgG1
Mouse IgG
Mouse IgM
Rat IgG2a
Mouse IgM

Isotype controls:
Species

Manufacturer

Mouse IgG1

Ebioscience

Mouse IgG3
Rat IgM
Mouse IgG1

Ebioscience
Ebioscience
R&D
Novus/Santa
Cruz

Fluorochrome(s)
unconjugated, FITC, alexa488, PE, APC, eFluor-450
unconjugated, FITC, alexa488, PE
unconjugated, alexa-488, PE
unconjugated, alexa-700

Rabbit IgG
Secondary antibodies:
goat anti-mouge IgG
donkey anti-mouse IgG
goat anti-rabbit IgG
goat anti-rat IgM

Fluorochrome(s)
unconjugated, alexa488, PE
unconjugated, alexa488, PE
unconjugated, alexa700
v450
PE
PE, APC
unconjugated
v450
APC
v450
ACP
PE, APC, eFluor-450
PE
PE, APC
APC
efluor-450
PE
v450
PE
PE
APC
APC, v450

unconjugated

Life technologies
Life technologies
Life technologies
Life technologies

Antibodies : used per manufacturer's
recommendations and concentrations
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alexa-488,PE , APC
alexa-488, PE, APC
alexa-488, PE, APC
alexa-488, APC

Immunohistochemistry
Right atrial specimens were cut longitudinally into 2-4 mm sections and fixed for
24 h with 10% neutral buffered formalin. Tissue fragments were ethanol dehydrated,
xylene cleared, and paraffin embedded. Paraffin embedded specimens were sectioned (4
µm) using a microtome, deparaffinized, and rehydrated. Antigen retrieval was performed
by incubating sections with DAKO citrate buffer solution for 10 min at 95°C. Slides were
next blocked in 5% BSA for 1 h prior to immunostaining. Immunostaining for SSEA-3,
SSEA-4, and c-kit was performed by staining overnight at 4°C with primary antibodies.
Primary antibody staining for α-sarcomeric actin, myosin heavy chain, and CD45 was
performed at room temperature for 1 h. After primary antibody labeling, the sections
were washed 3 times in 1X PBS for 3 min. Sections were incubated at room temperature
for 1 h with secondary antibodies, counterstained with DAPI, and permanently mounted
using vectashield. Images were taken on a Zeiss 510 confocal microscope and analyzed
with the accompanying Zeiss software with optimization of contrast and brightness
applied globally to the entire image. No extrinsic software was used to process or alter
images.
Immunocytochemistry
SSEA-3pos linneg cells were either seeded on chamber slides or immunolabeled in
suspension for immunocytochemical characterization. In both cases, primary antibody
labeling for SSEA-3, SSEA-4, and other cell surface markers was performed on live cells
followed by fixation in buffered 4% PFA, methanol permeabilization for additional
intracellular staining, and secondary staining with fluorophore conjugated antibodies.
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Briefly, cells that were seeded onto chamber slides were allowed to attach
overnight. Slides were then washed with 1X PBS and stained live with anti-human
SSEA-3- and SSEA-4-unconjugated antibodies (Ebioscience at 1:100 dilutions) for 1 h at
room temperature in 1% BSA MACS buffer. Slides were subsequently washed with 1X
PBS for 10 min, fixed with 4% PFA (Sigma) for 15 min at room temperature, and washed
with 1X PBS. Cells were permeabilized with methanol for additional intracellular
immunostaining in appropriate cases. Slides were incubated with secondary antibodies
conjugated with fluorophores (FITC, PE, TRITC, or APC) at room temperature (all
secondary antibodies were obtained from Life Technologies). After secondary labeling
and nuclear counterstaining with DAPI, slides were washed with 1X PBS and images
acquired.
Suspension immunostaining was performed with similar antibody concentrations,
incubation periods, fixation steps, and secondary antibody labeling as previously
described, but was followed with adhering cells to microscope slides via a Cytospin and
mounting with Vectashield mounting medium (Vector Labs). As before, all images were
taken with a Zeiss 510 confocal microscope and analyzed with the accompanying Zeiss
software. Image processing was performed relative to isotype control labeling with
integral instrument software only. Modifications to brightness and contrast of images
were applied to the entire image fields. No accessory image software was utilized to
adjust images. A list of antibodies utilized for immunohistochemistry/cytochemistry is
provided in supplemental Table 2.
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Table 2.
Immunohistochemistry/Immunocytochemistry
Marker
Manufacturer
hNA
SSEA-3
SSEA-4
WT-1
NANOG
OCT4
c-kit
c-kit
CD45
Tryptase
Sarcomeric actin
a-Myosin heavy chain
Smooth muscle actin
alpha-tubulin
connexin-43

Millipore
Ebioscience
Ebioscience
Sigma
Abcam
Ebioscience
DAKO
Santa Cruz
DAKO
DAKO
Sigma
Abcam
Sigma
Abcam
Sigma
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Species (anti-human)
Mouse IgG1
Rat IgM
Mouse IgG3a
Rabbit IgG
Rabbit IgG
Rat IgG
Rabbit IgG
Rabbit IgG
Mouse IgG
Mouse IgG
Mouse IgM
Mouse IgG
Mouse IgG
Mouse IgG1
Rabbit IgG

Doubling times
Cell population doubling times were calculated by exponential regression, where
doubling time (d) can be obtained by noting the number of final cells at time t [N(t)], the
initial number of cells seeded for expansion C, and the time the culture was allowed to
expand in hours t within the formula N(t)=C2t/d. Doubling times at passage 2-3 were
recorded and average doubling times for SSEA-3pos linneg cells at passage 3 calculated.
Cell counts were performed by hemocytometer and Trypan blue in duplicate.
Clonogenicity
Freshly MACS sorted human cardiac SSEA-3pos linneg cells were seeded onto
Terasaki plates using the limiting dilution technique. Wells with more than one cell were
marked and excluded from further analysis. In total, fifteen 72-well Terasaki plates were
seeded per patient. Six patients were utilized for the assay to calculate mean
clonogenicity of human SSEA-3pos linneg cells. Clonogenicity was defined as a visually
verified single cell proliferating to form a colony that completely covered the well. Wells
that had single cells that did proliferate but spontaneously senesced and did not result in
complete well coverage were deemed “negative”. The number of colonies formed was
divided by the original number of visually verified single cell wells to obtain a percent
for each patient’s cells. The percentages for each patient were averaged to obtain a mean
clonogenicity for human cardiac SSEA-3pos linneg cells.
qPCR
Total RNA was prepared from MACS/FACS sorted SSEA-3pos linneg and SSEA3neg linneg cells using PureLink® RNA Mini Kit (Life Technologies). cDNA was
synthesized from total RNA using the High-Capacity cDNA Reverse Transcription Kit
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(Life Technologies) with random hexamers primers according to the manufacturer's
instructions. Real-time PCR was performed using the Fast SYBR® Green Master Mix
(Life Technologies) per the manufacturer’s protocol. Reactions were performed in
duplicate on a 7900 Fast Real-Time PCR System (Applied Biosystems) at 95 °C for 30 s
and 40 cycles of 5 s at 95 °C, and 30 s at 60 °C. A negative control with RNA instead of
cDNA was carried out, and the integrity of PCR was verified by dissociation curve
analysis. Relative gene expression was quantified from fluorescence cycle threshold (Ct)
values using the ΔΔCt method. Primer sequences for all targets are listed in supplemental
Table 3.
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Table 3:
Gene name
BRY T
OCT4
MIXL1

Forward
GTGCTGTCCCAGGTGGCTTACA
GATG
GATGTGGTCCGAGTGTGGTTCT
GGATCCAGGTATGGTTCCAG

Reverse
CCTTAACAGCTCAACTCTAACT
ACTTG
TGTGCATAGTCGCTGCTTGAT
GGAGCACAGTGGTTGAGGAT

NANOG
TBX5
TBX18
TBX20
NKX2.5
GATA4

GCAGAAGGCCTCAGCACCTA
TTCTGCACTCACGTCTTTCC
CAACAGAATGGGTTTGGAAG
AGCTTTGGGACAAATTCCAT
CCCCTGGATTTTGCATTCAC
AAGACACCAGCAGCTCCTTC

AGGTTCCCAGTCGGGTTCA
TGGCAAAGGGATTATTCTCA
AAGGTGGAGGAACTTGCATT
CTTGGCCTCAGGATCCAC
CGTGCGCAAGAACAAACG
TGTGCCCGTAGTGAGATGAC

GATA6

AAAGAGGGAATTCAAACCAGGAA

KDR

GAGGAGAAGTCCCTCAGTGATGTAG

GAAGTTGGAGTCATGGGAATGG
ACTTGGAAGCTGTAACAGATGA
GATG

TERT
WT1
IGF-1R
GAPDH
Beta2
microglobulin
OCT4
NANOG
NKX2.5

CGTCGAGCTGCTCAGGTCTT
CCAGCCCGCTATTCGCAA
TGTCCTGACATGCTGTTTGA
TCAGACACCATGGGGAAG

AGTGCTGTCTGATTCCAATGCTT
CGAGTACTGCTGCTCACCCA
AGGCTCCATCTCCTCTTTGA
ACATGTAAACCATGTAGTTGAG

AATGCGGCATCTTCAAACCT
GATGTGGTCCGAGTGTGGTTCT
GCAGAAGGCCTCAGCACCTA
CCCCTGGATTTTGCATTCAC

TGACTTTGTCACAGCCCAAGATA
TGTGCATAGTCGCTGCTTGAT
AGGTTCCCAGTCGGGTTCA
CGTGCGCAAGAACAAACG

GATA4
MEF2C
GATA6

AACGACGGCAACAACGATAAT
CTGGCAACAGCAACACCTACA
AAAGAGGGAATTCAAACCAGGAA

KDR

GAGGAGAAGTCCCTCAGTGATGTAG

GTTTTTTCCCCTTTGATTTTTGATC
GCTAGTGCAAGCTCCCAACTG
GAAGTTGGAGTCATGGGAATGG
ACTTGGAAGCTGTAACAGATGA
GATG
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In vitro differentiation
For myogenic differentiation, cells were expanded in T75 flasks one passage after
sorting to obtain approximately 3-5 million SSEA-3pos linneg sorted cells. Cells were
trypsinized, seeded at a density of 104 cells/cm2 in 6-well plates, and allowed to attach
for 24 h in SSEA-3 cell growth media. Growth media was changed to myogenic
differentiation media [DMEM-LG (GIBCO), 5% horse serum (Life Technologies), 105M dexamethasone (Sigma), 0.75% DMSO (Sigma), 20 mmol/L ascorbic acid, 0.1% ITS
liquid media supplement (Sigma), 0.1% NEAA (Lonza), and 100 U/mL Pen-Strep.
Media was changed every 48 h without passaging for 35 days. Cells were harvested by
trypsinization at various time points for western blot analysis for myocyte and smooth
muscle contractile proteins. Additionally, cells were trypsinized and reseeded on
chamber slides for contractile protein immunostaining and confocal microscopy.
Endothelial differentiation was induced by changing full growth media to EGM2MV (Lonza) media supplemented with 60 ng/mL VEGF (PeproTech). EGM-2MV
media was replaced every 48 h during the 10 day duration of endothelial differentiation.
Cells were trypsinized at 90% confluence and reseeded at 40% confluence when visually
indicated in T75 flasks. Cells were trypsinized and submitted for flow cytometric
analysis for CD31 expression at days 0, 4, and 10 for comparison.
Western blot analyses
Cells were trypsinized, washed with 1X PBS, suspended in cell lysis buffer (1%
NP40, 150mM NaCl, 20mM Tris-HCl, 1% Triton X-100, 4mM PMSF, 1:100 Proteinase
Inhibitor Cocktail), and briefly sonicated. Whole cell lysates were centrifuged at 14,000 x
g for 20 min and resultant lysate protein concentrations determined using Bio-Rad
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Protein Assay Dye Reagent (Cat#500-0006). Whole cell lysates (15-40 µg of protein)
were resolved on 10-12% SDS-PAGE gels (Reagents from Bio-Rad), transferred to
PVDF membranes, and blocked in 3% milk TBST buffer at room temperature for 30 min.
Membranes were subsequently incubated with primary antibody in blocking buffer (3%
milk in TBST) overnight at 4°C, washed in 1X TBST, and incubated with HRPconjugated secondary antibodies at RT for 1 h. Membranes were then rinsed with 1X
TBST and proteins detected using enhanced chemiluminescence substrate (HyGOL,
Denville Scientific, Cat#E2500) according to the company instructions. Western blot
antibodies are listed in Table 4.
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Table 4:
Marker

Manufacturer

Cat#

Species

Mw

Usage

NKX2.5
NKX2.5
Brachyury
(T)
sm-MHC

abcam

ab91196

Ms IgG1

35kDa

WB, 1:1000

abcam

ab106923

Gt IgG

abcam

ab20680

Rb IgG

Sigma

M7786

Ms IgG1

35kDa
47, 53,
75kDa
200kDa

SMA

Sigma

A5228

Ms, IgG2a

42kDa

α-SA

Sigma

A7811

Ms IgG

42kDa

α-MHC

Novas

Ms IgG

250kDa

Ms, IgG2b

250kDa

Sigma

NB300-284
NBP2-36746
(CL2162)
C6219

Rb, IgG

43KDa

WB, 1:1000
WB:higher
1:1000
WB: 1:2000
WB:
1:10000
WB:higher
1:2500
WB:1:1000
WB: 1:5001000
WB: 1:8000

WT1
KDR
KDR

Sigma
Abcam
Sigma

WH0007490M1
Ab9530
SAB4300657

Ms IgG2bk
Ms, IgG1
Rb, IgG

WB, 1:500
WB, 1:500
WB, 1:500

vWF

Abcam

Ab6994

Rb, IgG

56KDa
220KDa
220KDa
500+
KDa

Cell Signaling
Tech

#3700

Rb, IgG

42kDa

WB :1:1000

MYH6
CX43

Anti-β-actin

Novas
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WB, 1:500

Cytokine Array
5×106 SSEA-3pos linneg or dermal fibroblasts were seeded in culture flasks in
identical conditions with FBS‐free F-12 media for 24 h. The supernatants (conditioned
media) were collected and the secretion of various cytokines was visualized by a semiquantitative Ab array (R&D biosystems). Intensity was determined using ImageJ
software (NIH) according to manufacturer’s specifications.
Animal studies
This study was performed in immunodeficient NOD/SCID (NOD.CB17Prkdcscid/J) female mice (age ~4 months), purchased from The Jackson Laboratory (Bar
Harbor, ME). All mice were maintained in micro-isolator cages under specific pathogenfree conditions in a room with a temperature of 24℃, 55–65% relative humidity, and a
12-h light–dark cycle.
Murine Model of Acute Myocardial Infarction and Intramyocardial Cell Delivery
The murine model of myocardial ischemia and reperfusion has been described in
detail20. Briefly, mice were anesthetized with sodium pentobarbital (60 g/kg i.p.) and
ventilated using carefully selected parameters. The chest was opened through a left
anterolateral thoracotomy, and a nontraumatic balloon occluder was implanted around the
mid-left anterior descending coronary artery using an 8–0 nylon suture. To prevent
hypotension, blood from a donor mouse was given at serial times during surgery. Rectal
temperature was carefully monitored and maintained between 36.7 and 37.3 ℃
throughout the experiment. In all groups, myocardial infarction (MI) was produced by a
45 min coronary occlusion followed by reperfusion.

105

The procedure for cell transplantation by intramyocardial injection was similar to
that used in our previous studies143. Briefly, 30 min after reperfusion, 2 ×105 human
cardiac SSEA-3pos linneg, an equivalent number of control cells (human dermal
fibroblasts obtained from ATCC), or an equivalent volume of vehicle were injected
intramyocardially using a 30-gauge needle. A total of four injections (10 µl each) were
made in the peri-infarct region in a circular pattern, at the border between infarcted and
non-infarcted myocardium. Mice were then allowed to recover for 39 days until
euthanasia and tissue collection.
Echocardiographic studies
Murine echocardiographic images were obtained with a Vevo 2100 high
frequency, high resolution (30 micron) digital imaging ultrasound system (VisualSonics,
Inc.) as previously described.20 Serial echocardiograms were obtained at baseline (4 days
prior to coronary occlusion/reperfusion and cell transplantation), 5 days after cell
transplantation, and 35 days after cell transplantation (4 days prior to hemodynamic
studies and euthanasia). All studies were performed under isoflurane anesthesia. Using a
rectal temperature probe, body temperature was carefully maintained between 36.7 and
37.3 ˚C throughout the study. Digital images were analyzed off-line by blinded observers
using the Vevo 2100 workstation software. At least three measurements were taken and
averaged for each parameter. Standard echocardiographic parameters were derived from
the two-dimensional, M-mode, and Doppler images, as in our previous studies.20
Speckle-tracking echocardiographic (STE) analysis was performed with the STE
software, which utilizes semi-automated border tracking (VisualSonics, Inc.), as detailed
in the online Supplement.
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Hemodynamic Studies
Hemodynamic studies were performed 39 days after cell or vehicle treatment, just
before euthanasia, using the ARIA-1 system and Millar catheter as described.141, 143
Briefly, mice were anesthetized with isoflurane and rectal temperature kept between 36.7
and 37.3 ˚C. A 1.0 French Millar catheter was inserted into the LV via the right carotid
artery. Inferior vena cava occlusion was performed with external compression to produce
variably loaded beats for determination of the end-systolic PV relation (ESPVR) and
other derived constructs of LV performance. As in the case of the echocardiographic
studies, all hemodynamic data analyses were performed off-line by investigators blinded
to treatment group.
Cardiac tissue fixation and morphometric analysis
At the conclusion of the in vivo study, the mouse heart was arrested in diastole by
an intravenous injection of 0.15 ml CdCl2 (100 mM), excised, and perfused retrogradely
at 70–80 mmHg (LVEDP = 8 mmHg) with heparinized PBS followed by 10% neutral
buffered formalin solution for 15 min. The heart was then sectioned into three slices from
apex to base, fixed in formalin for 24 h, and subjected to tissue processing and paraffin
embedding. Paraffin-embedded LV blocks were sectioned at a thickness of 4 µm for
histochemistry and immunohistochemistry. Morphometric parameters, including LV
cavity area, total LV area, risk region area, scar area, LV wall thickness, and infarct
expansion index were measured in sections stained with Masson’s Trichrome as
previously described.143 In each mouse heart, 4 – 5 slides were stained and analyzed.
From apex to base, the average distance between two stained slides was 120 - 150 um.
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Images were analyzed using NIH Image J (1.42v) and measurements from the various
slices per heart averaged.
Immunohistochemistry of murine cardiac specimens
Formalin-fixed, paraffin-embedded, 4 µm-thick heart sections were
deparaffinized in xylene and rehydrated gradually in a series of ethanol followed by
antigen retrieval procedure. After incubation with blocking solution, persistence of
transplanted human stem cells was determined by human nuclear antigen (HNA)
(Millipore) immunofluorescent staining and confocal microscopy. The fate of
transplanted cells was assessed by staining with specific antibodies against the myocyte
marker cardiac troponin I (cTnI) (Santa Cruz), endothelial cell marker isolectin IB4 (Life
Technologies), and smooth muscle cell marker α-smooth muscle actin (α-SMA) (Santa
Cruz). Proliferation of transplanted cells was evaluated by immunofluorescent staining of
nuclei for BrdU using a rat monoclonal antibody (Santa Cruz). In all of the
immunofluorescent staining procedures, secondary antibodies conjugated with the
appropriate fluorochromes (Jackson ImmunoResearch) were used. The concentration of
primary and secondary antibodies corresponded to that indicated by the manufacturers.
Immunohistochemical signals were acquired by confocal microscopy and quantitatively
analyzed by Image J (1.42q, NIH). In each heart, HNA+ nuclei, double positive cells
(HNA+/cTnI+, HNA+/IB4+, and HNA+/α-SMA+), triple positive cells
(HNA+/cTnI+/BrdU+, HNA+/IB4+/BrdU+, and HNA+/α-SMA+/BrdU+), and total nuclei
were counted in 25 confocal images acquired from the infarcted area (10), two border
zones (10), and noninfarcted area (5). In all cases, at least five hearts per group were
examined.
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Statistics
Student’s t-test, one-way ANOVA, or two-way repeated measures ANOVA, as
appropriate, was employed for comparisons of qPCR analyses as well as
echocardiographic, hemodynamic, and immunohistochemical studies of murine hearts.
All data are reported as means ± SEM.
Results
Localization of SSEA-3pos linneg cells in human right atrial tissue
Localization of human SSEA-3pos linneg cardiac cells was accomplished by
immunohistochemical staining of formalin fixed, paraffin embedded, human right atrial
tissue samples. Immunolabeling was performed not only for localization but also for
immunophenotypic characterization of the cells in situ with antibodies specific for c-kit
(CD117), CD34, CD45, SSEA-3, and SSEA-4.

SSEA-3pos linneg cardiac cells were

observed to be most highly prevalent within the subepicardium with a decreasing gradient
to the compact myocardium where they were mainly visualized as single or doubly
grouped cells within the interstitial space between myocytes (Fig. 16A and Fig. 17A-C).
SSEA-3pos linneg cells appropriately co-expressed SSEA-4 (Fig. 16B-D). In situ, SSEA3pos linneg cells were largely c-kit negative (Fig 16E-F); however, in very rare cases,
overlapping expression of c-kit [i.e. SSEA-3pos SSEA-4pos c-kitpos cells] was also
observed (Fig. 17D-G). SSEA-3 expression did not overlap with mature myocytes,
smooth muscle, endothelial cells, or cardiac fibroblasts.
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Figure 16. Cells expressing the embryonic stem cell-associate antigen SSEA-3 are
present in the human heart and lack hematopoietic lineage markers (linneg). A.
Transmission confocal microscopic image of human right atrial myocardium with
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immunolabeling of SSEA-3 (green) and SSEA-4 (red). SSEA-3pos cells (green) are
located in the cardiac interstitium between striated myocytes. Scale bar is 50um. B-D.
Immunolabeling of SSEA-3 (green), SSEA-4 (red), and DAPI nuclear counterstain
demonstrate that SSEA-3pos linneg cells appropriately co-express SSEA-4 (merged image).
E. SSEA-3pos linneg cells (green) in the white box (enlarged in panel F) lack c-kit
expression. Scale bar is 50um. F. A c-kitpos cell is shown in close proximity to the
SSEA-3pos linneg cells; this suggests that SSEA-3pos linneg cells are distinct from
previously described populations of cardiac progenitors. G-I. The prevalence of SSEA3pos linneg cells in human right atrial myocardium was quantified by flow cytometric
analysis after total enzymatic digestion of right atrial samples and was normalized to
milligrams of right atrial tissue from which the cells originated. G. An average of
1.13±0.27 x 105 nucleated cells were analyzed per human right atrial sample (n=12) after
complete enzymatic digestion. H. SSEA-3pos linneg cells accounted for 1.3±0.19% of total
nucleated cells obtained from right atrial samples. I. The prevalence of SSEA-3pos linneg
cells was 5.8±1.7 cells per milligram of human right atrial tissue (n=12).
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Figure 17. SSEA-3pos cardiac cells are located within the subepicardium and
myocardial interstitium predominantly as solitary cells, and a subpopulation of
SSEA-3 positive cells express c-kit, likely representing an intermediate phenotype of
cardiac progenitors. A-C. Shown (top) are three confocal microscopy images of solitary
SSEA-3pos cardiac cells (green) within formalin fixed adult human right atrial tissue
specimens from separate patients. D. This confocal microscopic image demonstrates
higher prevalence of SSEA-3pos cells within the subepicardium. The SSEA-3pos cells
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within the compact myocardium were observed as single cells within the interstitium as
shown in images A-C. SSEA-3pos (green) c-kitneg (red) cells are highlighted by arrows
and c-kitpos SSEA-3neg cells by arrowheads (scale is 20um). Notably, a cell expressing
both SSEA-3 and c-kit can be seen within the white box. E. An enlarged image of the
white box in image D shows the intermediate phenotype of SSEA-3 and c-kit positivity
(scale is 10um). F. Another example of an SSEA3pos c-kitpos cell within the white box.
SSEA-3pos c-kitneg cells are indicated by arrows and a c-kitpos SSEA-3neg cell marked by
the arrowhead (scale is 20um). G. A group of SSEA-3 expressing cells (arrowhead)
within the myocardial interstitium between striated myofibrils is shown within the white
box. These cells co-express SSEA-4 as shown on the right with fluorophore separated
images expanded from the white box. One of the cells was observed to also express c-kit
(arrow) in addition to SSEA-3 and SSEA-4. Scale bar is 10um. H. Flow cytometric based
quantitation of cells obtained from freshly digested right atrial tissue samples
demonstrated that cardiac SSEA-3pos linneg cells displayed partial overlap with SSEA-3
expression (69.2±3.4%, n=10) validating the in vivo observation shown in images D-G. I.
Immediately after enzymatic digestion, 7.18±1.78% of SSEA-3pos linneg cells coexpressed c-kit (n=10). Data are mean±SEM.
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Prevalence of SSEA-3pos linneg cells in human right atrial tissue in situ
The prevalence of SSEA-3pos linneg cells was quantified by immunolabeling of
cardiac cells obtained after total enzymatic digestion of human right atrial tissue samples
with antibodies specific to SSEA-3, CD34, and CD45. An average of 1.13±0.27 x 105
nucleated cells were analyzed per human right atrial sample (n=12). SSEA-3pos linneg cells
accounted for 1.3±0.19% of total nucleated cells obtained from right atrial samples after
robust enzymatic digestion. The prevalence of SSEA-3pos linneg cells was 5.8±1.7 cells
per milligram of right atrial tissue (Fig. 16G-I).
Quantification of overlapping c-kitpos and SSEA-3pos linneg populations in situ
Quantification of c-kitpos and SSEA-3pos populations was performed by
immunolabeling and flow cytometric analysis (excluding CD34pos/45pos cells) after
complete enzymatic digestion of right atrial tissue samples (n=10). C-kitpos linneg cardiac
cells demonstrated a high degree of overlap with SSEA-3 expression (69.2±3.41%).
However, SSEA-3pos linneg cells demonstrated much less overlap with c-kit coexpression: only 7.18±1.78% of SSEA-3pos linneg cells showed co-expression of c-kit
(Fig. 17H-I) as assessed by flow cytometric analysis immediately after total enzymatic
digestion.
SSEA-3 immunoselection confers enrichment for markers associated with stemness
and early cardiac commitment
After enzymatic digestion of right atrial tissue and primary expansion of tissue
culture plate adherent cardiac cells, passage 1 cells were immunolabeled with antibodies
specific to SSEA-3 and c-kit. To validate the utility of SSEA-3 as a surrogate stemness
associated cell surface molecular target by which cardiac precursors may be selected for
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and isolated, SSEA-3pos linneg cells were FACS sorted for qPCR comparison with
unsorted cardiac cells to determine if selection of cells expressing SSEA-3 results in
enriched expression of the pluripotency associated markers OCT4 and NANOG as well
as early and late cardiac markers NKX2.5 and GATA4 and MEF2C, respectively. SSEA3pos linneg cardiac cells demonstrated higher expression of OCT4 (62.5±26.33 fold,
P<0.05) and NANOG (89.7±42.6, P<0.05) as well as the early cardiac marker NKX2.5
(137.3±75.3, P<0.05) (n=5), albeit at relatively low levels compared with the internal
control (GAPDH or β2-microglobulin). There was no enrichment of GATA4 or MEF2C
transcript expression in SSEA-3 expressing cells (Fig. 3) compared with unsorted cardiac
cells. All SSEA-3pos linneg cardiac cells at passage 1 lacked expression of the
hematopoietic markers CD34 and CD45 (data not shown) and showed adherence to
plastic culture plates, indicating that these cells are not hematopoietic progenitors (which
are non-adherent to tissue culture plates) and are not immediately from the bone marrow.

115

Figure 18. SSEA-3 immunoselection: Enrichment of pluripotency associated
markers, cardiac mesodermal markers, isolation and expansion. A. A representative
FACS sorting plot of SSEA-3pos linneg cardiac cells at passage 2 is shown with sorting
gate R4 (center panel) established with respect to isotype control (left panel) for false
positivity <1%. In this patient, SSEA-3pos linneg cells were 2% of the total in vitro
expanded cell population that were FACS sorted for qPCR-based comparison.
Comparison of SSEA-3pos linneg FACS sorted cells to the unsorted population by qPCR
demonstrated enriched relative expression of OCT-4 (62.5±26.33 fold, P<0.05), NANOG
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(89.7±42.6, P<0.05), and NKX2.5 (137.3±75.3, P<0.05), n=5. B. Flow cytometric
analysis of resultant magnetically sorted SSEA-3pos linneg cardiac cells is shown with
gates established by isotype control <1% false positivity in P7 (left panel).
Immunomagnetically sorted SSEA-3pos cells were 94% positive for SSEA-3 after MACS
sorting in this particular patient. A representative light microscopic image of SSEA-3pos
linneg cardiac cells is shown in the right panel (10x magnification). C. Confocal images of
SSEA-3pos linneg cells (green) are shown in the left (10 um scale) and center (100 um
scale). SSEA-3pos linneg cells at passage 2-3 demonstrated an average doubling time of
26.5±2.11 h (n=9 patients). D. Immunomagnetically selected SSEA-3pos linneg cardiac
cells were assessed by flow cytometric analysis at the end of passage 2 for SSEA-3
positivity. A mean SSEA-3 positivity of 81.4±2.34% was achieved demonstrating
reproducibility of isolation and in vitro expansion (n=32). E. Doubling times of
immunomagnetically selected SSEA-3pos linneg cells calculated during passage 2-3
averaged 26.5±2.1 h.
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Validation of clinically relevant methods of SSEA-3pos linneg cell isolation and
expansion
SSEA-3pos linneg cells could be sorted and enriched with high efficiency. A
representative flow cytometric plot of MACS enriched SSEA-3pos linneg cells as well as
phase contrast and confocal microscopic immunocytochemical images of freshly MACS
sorted SSEA-3pos linneg cardiac cells prior to passage 2 in vitro expansion are shown (Fig.
18). In vitro expansion of SSEA-3pos linneg cells yielded approximately 3-5 x 106 cells at
the end of passage 2 (demonstrating an average SSEA-3 positivity of 81.4±2.34%, n=32)
which were able to be expanded exponentially to 30-50 x 106 cells by the end of passage
3 for potential therapeutic utilization. The doubling time of SSEA-3pos linneg cells at
passage 2-3 averaged 26.5±2.11 h (n=9) (Fig. 18).
To validate the MACS based sorting methodology, a similar comparison of
immuno-magnetically (MACS) selected SSEA-3pos linneg cardiac cells with the negatively
sorted fraction was performed via qPCR (Fig. 4). MACS selection of cells expressing
SSEA-3 demonstrated consistent enrichment of cells expressing higher levels of NANOG
(30.7±5.63 fold), OCT4 (8.48±2.01), MIXL1 (45.4±6.6), NKX2.5 (14.8±3.73), and
TERT (48.2±13.3), P<0.05 (Fig 4A). NANOG was detected by immunostaining with
nuclear localization in some SSEA-3pos cells (Fig. 4D). KDR and GATA6 exhibited a
trend toward enrichment; however this was not statistically significant. Although there
was no significant difference in the expression of TBX5, TBX18, TBX20, or GATA4
transcripts between SSEA-3pos and SSEAneg cells, qPCR cycle times revealed relatively
high expression of TBX18, TBX20, and GATA4 in both populations (data not shown).
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TBX5 was detectable by qPCR, but lowly expressed in both SSEA3pos and SSEA3neg
sorted cells (data not shown). Transcripts for ISL-1 and MESP1 were not detected.
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Figure 19. Characterization of in vitro expanded SSEA-3pos linneg. A. qPCR of
immunomagnetically selected SSEA-3pos cardiac cells demonstrated similar patterns of
enrichment for pluripotency associated markers NANOG (30.6±5.63) and OCT4
(8.48±2.01), early cardiac mesodermal markers MIXL1 (45.4±6.60) and NKX2.5
(14.8±3.73), and telomerase reverse transcriptase, TERT (48.15±13.3), P<0.05. B. Flow
cytometric analyses of in vitro expanded SSEA-3pos linneg cells isolated from 6 human
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right atrial tissue samples consistently demonstrated a mesenchymal phenotype with near
complete positivity for CD105 (98.8±0.43%), CD73 (98.8±0.74%), CD29 (99.5±0.11%),
CD44 (99.5±0.31%), CD166 (96.7±3.90%), and HLA class 1 (97.4±1.18%) and
heterogeneity of CD90 (59.6±4.77%) expression. SSEA-3pos linneg cells lacked
expression of hematopoietic markers CD34 and CD45 (0.53±0.09%), c-kit (0.28±0.06%),
CD31 (0.48±0.13%) and HLA class 2 (0.35±0.11%). Heterogeneity of KDR expression
was observed (7.0±0.56%). C. As SSEA-3 expression was observed to decrease over
time and with passaging, qPCR performed after SSEA-3 re-enrichment by
immunoselection of cells retaining SSEA-3 expression at advanced passage (passage 9)
showed continued enrichment of pluripotency associated markers NANOG (89.6±23.3)
and OCT4 (44.6±14.0) as well the early cardiac marker NKX2.5 (57.6±19.0) compared
with that of the SSEA-3 negative fraction. GATA4 and GATA6 expression was not
observed to differ significantly. Asterisks mark statistical significance with P<0.05 in all
graphs.
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Immunophenotypic analyses of SSEA-3pos linneg cells
SSEA-3pos linneg cardiac cells at passage 2 were analyzed by flow cytometry for
co-expression of mesenchymal, endothelial, and hematopoietic lineage markers (Fig. 20).
SSEA-3pos linneg cells demonstrated a predominantly mesenchymal phenotype, with near
complete positivity for CD105 (98.8±0.43%), CD73 (98.8±0.74%), CD29 (99.5±0.11%),
CD44 (99.5±0.31%), CD166 (96.7±3.90%), and human leukocyte antigen (HLA) class 1
(97.4±1.18%) and heterogeneity for CD90 (59.6±4.77%) and KDR (7.0±0.56%)
expression (Fig. 20). SSEA-3pos linneg cells lacked the endothelial marker CD31
(0.48±0.13%), hematopoietic lineage markers CD34 and CD45 (0.53±0.09%), and HLA
class 2 (0.35±0.11%). Despite showing positivity for SSEA-3 and SSEA-4, in vitro
expanded cells did not express the tumor related antigen (TRA)-1-60 or TRA-1-81 that
are commonly observed, in addition to SSEAs, in iPSCs and ESCs.207 Although
overlapping c-kit expression was observed in situ (vide supra) (~ 8% of SSEA-3pos linneg
cardiac cells immediately after total enzymatic digestion, n=10) (Fig. 17), analyses at
passage 2 after in vitro expansion did not demonstrate any appreciable c-kit expression
(0.28±0.06%), indicating that c-kit expression is transient, that SSEA-3pos c-kitpos cells do
not expand in the present culture conditions, or that SSEA-3pos c-kitpos cells proliferate at
a much slower rate than SSEA-3pos c-kitneg cells, if they are in fact separate populations.
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Figure 20. Immunophenotype of in vitro expanded SSEA-3pos linneg CPCs. Flow
cytometric detection of progenitor (SSEA3, C-KIT), endothelial (CD31, KDR),
mesenchymal (CD29, CD44, CD73, CD90, CD105, CD166), human leukocyte (HLA-1,
HLA-II), and hematopoietic (CD34/45) cell surface antigens in SSEA-3pos linneg CPCs.
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TBX18 has been observed to be expressed in proepicardial progenitors110,
although recent evidence suggests that it is not completely confined to this compartment
within the fetal or mature heart.111 Therefore, our observation of TBX18 mRNA
expression within SSEA-3pos linneg cells (vide supra) cannot conclusively link these cells
to a particular cardiac progenitor lineage from fetal development. In contrast, Wilms
tumor gene 1 (WT-1), a marker with significant overlapping expression with TBX18, has
been utilized to exclusively define and track distinct proepicardial lineage derivatives,
epicardial derived cells (EPDCs), and epicardial epithelial to mesenchymal transition
(EMT) during cardiac development.84, 104, 105 WT-1 has also been demonstrated to be
expressed in response to myocardial injury within epicardial cells, essentially reactivating
a fetal gene program for cardiac repair after infarction.197, 210, 211 We observed WT-1
expression within in vitro expanded SSEA-3pos linneg cells. Immunostaining showed
primarily nuclear with some cytoplasmic localization of WT-1 (Fig. 19E). PCR analysis
of SSEA-3pos linneg cells confirmed transcript expression of WT-1 (Fig. 21). Observation
of WT-1 expression may suggest SSEA-3pos linneg cells are originally of proepicardial
origin. Incidentally, SSEA-3pos linneg cells also demonstrated robust expression of IGF1R by PCR (Fig. 21) similar to other described cardiac derived cell populations.212
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Figure 21. Validation of PCR products. Shown are representative gels validating
target sizes of PCR products ensuring specificity and appropriate target size with negative
controls.
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SSEA-3pos linneg cells are clonogenic and display multipotent differentiation potential
toward myocytes, smooth muscle, and endothelial cells
Freshly sorted human cardiac SSEA-3pos linneg cells were plated at low density in
suspension culture for assessment of their ability to expand and form spheres
spontaneously, which would indirectly imply clonogenic ability. SSEA-3pos linneg cells
formed spheres in suspension culture resembling previously described cardiospheres (Fig.
22A).213 Spheres were allowed to expand; replating of spheres on normal tissue culture
plates resulted in expansion of cells contained within the spheres, confirming that the
spheres consisted of viable cells. The cell surface immunophenotype of SSEA-3pos linneg
cells that were expanded in suspension and allowed to form spheres did not differ, after
replating and in vitro expansion, from those expanded in adherent monolayer conditions.
The immunophenotype of SSEA-3pos linneg cells was similar to that of cardiospherederived cells214, 215 as well as c-kit sorted cardiac cells140 with respect to cell surface CD
marker expression (Fig. 20).
Terasaki plates were seeded by limiting dilution with one cell per well to evaluate
clonogenicity. Singly seeded SSEA-3pos linneg cells formed colonies at an average
frequency of 21.16±3.8%, n=8. Representative single cell cloning progression is shown
in Figure 22B.
SSEA-3pos linneg cells at passage 2 were placed in directed differentiation
conditions to induce myocyte, smooth muscle, and endothelial differentiation.
Immunocytochemistry of cells placed in myogenic differentiation conditions
demonstrated upregulation of the sarcomeric proteins alpha-myosin heavy chain (αMHC) and α-sarcomeric actin after 35 days (Fig. 22C). Connexin 43 expression was
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visualized at sites of cell-cell contact, indicating functional gap junction formation
between adjacent cells (Fig. 22B). However, the staining pattern of sarcomeric proteins
did not yield mature, striated sarcomeric structures, indicating incomplete differentiation.
Robust smooth muscle differentiation was observed, with marked upregulation of smooth
muscle actin and upregulation of smooth muscle myosin heavy chain (Fig. 22E). After
differentiation, cell morphology was consistent with mature appearing smooth muscle
cells. Endothelial differentiation conditions resulted in marked upregulation of CD31
(PECAM) by immunostaining and confocal microscopy (Fig. 22F) and flow cytometric
analysis (Fig. 22G), with changes in morphology resembling typical endothelial cells.
Flow cytometric analysis of SSEA-3pos linneg cells during endothelial differentiation
demonstrated upregulation of CD31 at day 4 and appropriate down regulation of SSEA-3.
By day 10, >75% of cells had become CD31 positive with complete loss of SSEA-3
expression. Endothelial differentiated cells formed tubes when seeded in matrigel,
demonstrating phenomena typical of functional endothelial cells (Fig. 22H).
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Figure 22. SSEA-3pos linneg cells display clonogenic and multipotent differentiation
capacities expressing mature cardiac markers of myocytes, smooth muscle, and
endothelial cells under directed in vitro differentiation conditions. A. SSEA-3pos linneg
cardiac cells demonstrated the ability to form expanded spheres in suspension when
seeded at very low density, indicative of clonogenic ability. Attached SSEA-3pos linneg
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cells are shown after immunoselection (top left panel). Multicellular spheres formed and
expanded after low density seeding in suspension culture (center panels). These
multicellular spheres contained viable cells as evidenced by the attachment and
expansion of cells when seeded into normal tissue culture plates (right image). B. True
clonogenic ability was evaluated by singly seeded SSEA-3pos linneg cardiac cells in
Terasaki plates shown (left) with enlarged image expanded in the box. Clonogenic
expansion is seen in the center panel with four cells having originated from a single
SSEA-3pos linneg, ultimately giving rise to a colony (right panel). Singly seeded SSEA-3pos
linneg cells from different human patients formed clonal colonies in Terasaki plates at an
average frequency of 21.16±3.8% as shown in the bar graph on the right (n=8). Values in
graphs are represented as mean±SEM. C. Immunocytochemistry showing expression of
alpha-myosin heavy chain (green) and alpha-sarcomeric actin (red) after directed
myogenic differentiation. Nuclei were counterstained with DAPI (blue). D.
Differentiated SSEA-3pos linneg cells formed gap junctions with adjacent cells highlighted
by connexin 43 (red) expression (arrow) and alpha-tubulin (green). E. SSEA-3pos linneg
cells robustly formed smooth muscle like cells illustrated by smooth muscle actin (green)
expression. F. Expression of CD31 (magenta) is shown resulting from 10 days of
endothelial directed differentiation conditions. G. The time course of endothelial
differentiation is illustrated over 10 days for SSEA-3 positive cells [81% SSEA-3pos/<1%
CD31pos] at day 0 with respect to isotype control. CD31 was upregulated at day 4 and
robustly at day 10 [78% CD31pos] with loss of SSEA-3 during differentiation (<1% at day
10). Functional capacity with endothelial tube formation of CD31pos differentiated
SSEA-3pos linneg CPCs is shown in the right panel. Scale bars are 50um.
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SSEA-3pos linneg cells induce cardiac repair and functional recovery after
ischemia/reperfusion injury
The effect of SSEA-3pos linneg cardiac cell administration on LV remodeling after
myocardial infarction was investigated by morphometric analysis of Masson’s trichrome
stained sections (Fig. 23A). Although the LV risk region was similar across all groups
(Fig. 23B), mice that received SSEA-3pos linneg cells exhibited a statistically significant
increase in viable myocardium relative to vehicle (Fig. 23A&B). Further, as there were
no significant differences in mean anterior wall (infarcted wall) thickness across groups,
LV expansion indices were markedly reduced in SSEA-3pos linneg cell-treated animals
relative to vehicle (Fig. 23C).
The effect of SSEA-3pos linneg cardiac cell therapy on ventricular volume and
function after myocardial infarction was investigated by echocardiographic analyses and
Millar methodology. Significantly reduced left ventricular end-diastolic (Fig. 24A) and
end-systolic (Fig. 24B) volumes were observed in the SSEA-3pos linneg cell treatment
group compared to vehicle treated controls. Accordingly, measurements of left
ventricular ejection fraction were significantly higher in the SSEA-3pos linneg cell
treatment group compared to controls by both single plane B-mode (44.4±2.8% vs.
29.8±2.8%) and Simpson’s biplane (44.8±2.5% vs. 31.3±1.8%) methods of assessment.
In the setting of comparable body weights and heart rates between the treatment and
control group (data not shown), high ejection fraction in the cell treatment group
translated to increased stroke work and total cardiac output in SSEA-3pos linneg cell treated
hearts.
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Figure 23. Left ventricular morphometric analyses. Vehicle (black), cell control
(white), and SSEA-3pos linneg cells (grey) groups. Serial echocardiographic studies were
performed under isoflurane anesthesia at baseline (4 days prior to surgery) and 5 and 35
days after myocardial infarction. Data are mean ± SEM. A. Mason’s trichome staining
shows increased viable myocardium and decreased scar size in a representative crosssection of the left ventricle from a cell treated heart vs. that of control. B. Viable tissue
was significantly larger with similar size of risk region in the cell treated hearts over
those of controls.
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Figure 24. Left ventricular volumetric comparison. Left ventricular end diastolic and
end systolic volumes were assessed by Simpson’s method echocardiography comparing
SSEA-3pos linneg cells (EA-CPC) treatment and vehicle control groups at baseline, 5 days
and 35 days after I/R injury. A. The average left ventricular end diastolic volume was
significantly smaller in the SSEA-3pos linneg cells treatment group (67.0ul) vs that of the
control (79.9ul) indicating less adverse LV remodeling and less decompensatory LV
dilatation in the SSEA-3pos linneg cells treatment group. B. Similarly, end systolic
volumes were significantly smaller in the SSEA-3pos linneg cells treatment group than
control group. Human SSEA-3pos linneg cells abrogate LV dilatation and adverse
remodeling after ischemia/reperfusion injury that is known to lead to heart failure as well
as promote restoration of systolic function after ischemic injury. There was no difference
between groups at baseline or at 5 days (p>0.05) indicating similar starting cohorts of
female SCID mice and similar initial ischemic cardiac injury.
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Figure 25. Ejection Fraction. Echocardiography (echo) was performed for left
ventricular functional assessment in an immunocompromised murine model (SCID mice)
of ischemia/reperfusion (I/R) injury and subsequent human SSEA-3pos linneg cell
intramyocardial administration. Echo was performed at baseline prior to injury as well as
5 days and 35 days post I/R with subsequent cell therapy by intramyocardial injection of
200K human SSEA-3pos linneg cells or normal saline control in the border zones of the
infarction area. A. Significant improvement in cardiac function was seen over 35 days in
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the SSEA-3pos linneg cells treatment group (EA-CPCs) vs that of the control group
(CTRL). The control group had an average ejection fraction (EF) of 29.8% while the
human SSEA-3pos linneg cell treated group saw significant functional improvement to
44.4% (p<0.05) as measured in B Mode echocardiography. B. Ejection fraction assessed
by Simpson’s method echocardiography showed similar a pattern of improvement in the
SSEA-3pos linneg cell (EA-CPC) treatment with 44.8% EF vs. 31.3% EF in the control
group. There was no significant difference between groups at baseline or at 5 days by
either measurement methodology indicating no difference in starting populations/cohorts
of SCID mice and no difference in the extent of induced myocardial injury.
Improvements observed at 35 days are solely due to the treatment with SSEA3pos linneg cells (EA-CPCs).
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Figure 26. Stroke work and cardiac output. A.Stroke work and B. cardiac output were
measured by standard Millar methodology. These functional parameters were observed
to be significantly increased/improved as a result of human SSEA-3pos linneg cells
administration vs vehicle control in SCID mice that had undergone ischemic injury as
previously outlined.
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Discussion
In summary, we have provided for the first time direct evidence of the existence
of multipotent SSEA-3pos linneg cardiac progenitor cells, which are not a culture derived
phenotype but exist in the native human neonatal and adult myocardium. We have
shown for the first time that these SSEA-3pos linneg cardiac progenitor cells can be isolated
and expanded in vitro for the ultimate purpose of use in inducing repair of damaged
and/or poorly functioning myocardium. To confirm that these cells truly have a
phenotype expected of progenitor cells, we have performed the most extensive
characterization ever attempted in any adult progenitor cell population. We validated not
only the expression of markers such as pluripotent stem cell associated markers of oct4
and nanog but also telomerase, which allows these cells to preserve their progenitor
phenotype and avoid excessive shortening of their telomeres with repetitive cell
proliferation in vitro. Thusly, these cells retain a large proliferative reserve allowing
sufficient numbers of cells for a therapeutic cell product of SSEA-3pos linneg cells to be
generated. We have shown these cells possess a cardiac predisposition as they have
heterogeneous baseline expression of transcription factors showing early commitment to
mature cardiac lineages of endothelial, smooth muscle, and cardiomyocytes.
Furthermore, SSEA-3pos linneg cardiac progenitor cells up-regulate mature sarcomeric
proteins of smooth muscle and myocytes as well as surface markers and functional
characteristic of endothelial cells in in vitro myogenic and endothelial differentiation
conditions respectively. In other words, SSEA-3pos linneg cardiac progenitor cells have
cardiac multilineage potential. This pattern of gene expression and organ specific
predisposition is unique to progenitor cells isolated from the human heart and in contrast
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to any ability of other non-embryonic or neonatal non-cardiac stem cell populations (i.e.
MSCs from various tissues other than heart, HSCs, non-cardiac local tissue progenitors)
whose native function is not to contribute directly to lineages of the heart or directly to its
homeostasis. We have shown that our methods of isolation and expansion are
reproducible, and that SSEA-3pos linneg cardiac progenitor cells populations from different
patients have very similar progenitor gene expression patterns. We have utilized
clinically relevant methodologies that show exactly the characteristics and capabilities of
SSEA-3pos linneg cardiac progenitor cells that would be used in a clinically relevant
therapeutic application. With these methodologies we have verified within a model of
ischemically damaged myocardium that administration of SSEA-3pos linneg cardiac
progenitor cells can induce cardiac repair and abrogate adverse myocardial remodeling
that leads to functional decompensation. Again, to our knowledge, a comprehensive
report of the discovery, isolation, characterization, and evidence of therapeutic utility of
this kind, related to adult progenitor cells, has never been put forth. The clinically
applicable methodology demonstrated above enables rapid bench to bedside applications.
Future directions
Presently, analyses of the SSEA-3pos linneg cardiac progenitor cell treated hearts
are underway to evaluate whether donor cells engrafted into recipient hearts. Moreover,
did donor cells differentiate into mature cardiac phenotypes representing true
regeneration? If this is not observed, it would indicate primarily a paracrine action of
these cells on the recipient myocardium by which preservation and recovery of LV
function was observed compared to controls, similar to other cell types utilized for
cardiac cell based therapies to date. Regardless of whether the SSEA-3pos linneg cardiac
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cells work by engrafting and differentiating into mature myocytes or via paracrine
mechanisms, the discovery of this heretofore unknown cell population is an important
advance in the field of cell therapy and may have significant therapeutic applications.
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